{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:11:24Z","timestamp":1792800684168,"version":"4.5.0"},"reference-count":264,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"MSc-ABM Capstone Project from the Yong Loo Lin School of Medicine, National University of Singapore","id":[{"id":"https:\/\/ror.org\/01tgyzw49","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Core funding from the Bioinformatics Core, Immunology Translational Research Program"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-025-03992-w","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T06:04:46Z","timestamp":1769148286000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Sorafenib nanomedicine in HCC: nano-bio interactions and combination therapies"],"prefix":"10.1186","volume":"24","author":[{"given":"Tingxuan","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenshi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina H. K.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhou","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"3992_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:6.","journal-title":"Nat Rev Dis Primers"},{"key":"3992_CR2","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1007\/s10620-019-05537-2","volume":"64","author":"M Sayiner","year":"2019","unstructured":"Sayiner M, Golabi P, Younossi ZM. Disease burden of hepatocellular carcinoma: a global perspective. Dig Dis Sci. 2019;64:910\u20137.","journal-title":"Dig Dis Sci"},{"key":"3992_CR3","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","volume":"16","author":"JD Yang","year":"2019","unstructured":"Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16:589\u2013604.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3992_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174387","volume":"13","author":"M Borgia","year":"2021","unstructured":"Borgia M, Dal Bo M, Toffoli G. Role of virus-related chronic inflammation and mechanisms of cancer immune-suppression in pathogenesis and progression of hepatocellular carcinoma. Cancers. 2021;13:4387.","journal-title":"Cancers"},{"key":"3992_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030641","volume":"12","author":"MG Refolo","year":"2020","unstructured":"Refolo MG, Messa C, Guerra V, Carr BI, D\u2019Alessandro R. Inflammatory mechanisms of HCC development. Cancers. 2020;12:641.","journal-title":"Cancers"},{"key":"3992_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.20892\/j.issn.2095-3941.2022.0449","volume":"20","author":"C Yao","year":"2023","unstructured":"Yao C, Wu S, Kong J, Sun Y, Bai Y, Zhu R, et al. Angiogenesis in hepatocellular carcinoma: mechanisms and anti-angiogenic therapies. Cancer Biol Med. 2023;20:25\u201343.","journal-title":"Cancer Biol Med"},{"key":"3992_CR7","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1158\/1078-0432.CCR-18-1254","volume":"25","author":"MA Morse","year":"2019","unstructured":"Morse MA, Sun W, Kim R, He AR, Abada PB, Mynderse M, et al. The role of angiogenesis in hepatocellular carcinoma. Clin Cancer Res. 2019;25:912\u201320.","journal-title":"Clin Cancer Res"},{"key":"3992_CR8","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/nrclinonc.2011.30","volume":"8","author":"AX Zhu","year":"2011","unstructured":"Zhu AX, Duda DG, Sahani DV, Jain RK. HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol. 2011;8:292\u2013301.","journal-title":"Nat Rev Clin Oncol"},{"key":"3992_CR9","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378\u201390.","journal-title":"N Engl J Med"},{"key":"3992_CR10","doi-asserted-by":"publisher","first-page":"11851","DOI":"10.1158\/0008-5472.CAN-06-1377","volume":"66","author":"L Liu","year":"2006","unstructured":"Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, et al. Sorafenib blocks the RAF\/MEK\/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC\/PRF\/5. Cancer Res. 2006;66:11851\u20138.","journal-title":"Cancer Res"},{"key":"3992_CR11","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1038\/aps.2012.76","volume":"33","author":"W-f Mao","year":"2012","unstructured":"Mao W-f, Shao M-h, Gao P-t, Ma J, Li H-j, Li G-l, et al. The important roles of RET, VEGFR2 and the RAF\/MEK\/ERK pathway in cancer treatment with sorafenib. Acta Pharmacol Sin. 2012;33:1311\u20138.","journal-title":"Acta Pharmacol Sin"},{"key":"3992_CR12","doi-asserted-by":"publisher","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","volume":"64","author":"SM Wilhelm","year":"2004","unstructured":"Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43\u20139006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099\u2013109.","journal-title":"Cancer Res"},{"key":"3992_CR13","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s00280-006-0393-4","volume":"59","author":"YS Chang","year":"2007","unstructured":"Chang YS, Adnane J, Trail PA, Levy J, Henderson A, Xue D, et al. Sorafenib (BAY 43\u20139006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol. 2007;59:561\u201374.","journal-title":"Cancer Chemother Pharmacol"},{"key":"3992_CR14","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1200\/JCO.2005.06.124","volume":"23","author":"D Strumberg","year":"2005","unstructured":"Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43\u20139006 in patients with advanced refractory solid tumors. J Clin Oncol. 2005;23:965\u201372.","journal-title":"J Clin Oncol"},{"key":"3992_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2024.102434","author":"Y Liang","year":"2024","unstructured":"Liang Y. Mechanisms of sorafenib resistance in hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2024. https:\/\/doi.org\/10.1016\/j.clinre.2024.102434.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"3992_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15122691","volume":"15","author":"JC Mans","year":"2023","unstructured":"Mans JC, Dong X. The development of lipid-based sorafenib granules to enhance the oral absorption of sorafenib. Pharmaceutics. 2023;15:2691.","journal-title":"Pharmaceutics"},{"key":"3992_CR17","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.powtec.2015.04.044","volume":"283","author":"DH Truong","year":"2015","unstructured":"Truong DH, Tran TH, Ramasamy T, Choi JY, Choi H-G, Yong CS, et al. Preparation and characterization of solid dispersion using a novel amphiphilic copolymer to enhance dissolution and oral bioavailability of sorafenib. Powder Technol. 2015;283:260\u20135.","journal-title":"Powder Technol"},{"key":"3992_CR18","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1208\/s12249-017-0901-3","volume":"19","author":"H Wang","year":"2018","unstructured":"Wang H, Wang H, Yang W, Yu M, Sun S, Xie B. Improved oral bioavailability and liver targeting of sorafenib solid lipid nanoparticles in rats. AAPS PharmSciTech. 2018;19:761\u20138.","journal-title":"AAPS PharmSciTech"},{"key":"3992_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117118","volume":"177","author":"Q-q Fan","year":"2024","unstructured":"Fan Q-q, Tian H, Cheng J-x, Zou J-b, Luan F, Qiao J-x, et al. Research progress of sorafenib drug delivery system in the treatment of hepatocellular carcinoma: an update. Biomed Pharmacother. 2024;177:117118.","journal-title":"Biomed Pharmacother"},{"key":"3992_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01320-5","volume":"15","author":"H Tian","year":"2022","unstructured":"Tian H, Zhang T, Qin S, Huang Z, Zhou L, Shi J, et al. Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies. J Hematol Oncol. 2022;15:132.","journal-title":"J Hematol Oncol"},{"key":"3992_CR21","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1080\/09205063.2023.2230845","volume":"34","author":"F Liu","year":"2023","unstructured":"Liu F, Meng L, Wang H, Du C, Zhu J, Xiong Q, et al. Research on preparation and antitumor activity of redox-responsive polymer micelles co-loaded with sorafenib and curcumin. J Biomater Sci Polym Ed. 2023;34:2179\u201397.","journal-title":"J Biomater Sci Polym Ed"},{"key":"3992_CR22","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1177\/0885328219849711","volume":"34","author":"W Zhang","year":"2019","unstructured":"Zhang W, Cai J, Wu B, Shen Z. Ph-responsive hyaluronic acid nanoparticles coloaded with sorafenib and cisplatin for treatment of hepatocellular carcinoma. J Biomater Appl. 2019;34:219\u201328.","journal-title":"J Biomater Appl"},{"key":"3992_CR23","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.msec.2016.05.036","volume":"67","author":"A Heidarinasab","year":"2016","unstructured":"Heidarinasab A, Panahi HA, Faramarzi M, Farjadian F. Synthesis of thermosensitive magnetic nanocarrier for controlled sorafenib delivery. Mater Sci Eng C Mater Biol. 2016;67:42\u201350.","journal-title":"Mater Sci Eng C Mater Biol"},{"key":"3992_CR24","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.actbio.2019.05.028","volume":"92","author":"Y Wang","year":"2019","unstructured":"Wang Y, Yu H, Zhang D, Wang G, Song W, Liu Y, et al. Co-administration of combretastatin A4 nanoparticles and sorafenib for systemic therapy of hepatocellular carcinoma. Acta Biomater. 2019;92:229\u201340.","journal-title":"Acta Biomater"},{"key":"3992_CR25","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1080\/10717544.2019.1580797","volume":"26","author":"M Lei","year":"2019","unstructured":"Lei M, Ma G, Sha S, Wang X, Feng H, Zhu Y, et al. Dual-functionalized liposome by co-delivery of paclitaxel with sorafenib for synergistic antitumor efficacy and reversion of multidrug resistance. Drug Deliv. 2019;26:262\u201372.","journal-title":"Drug Deliv"},{"key":"3992_CR26","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamaoncol.2019.0250","volume":"5","author":"M He","year":"2019","unstructured":"He M, Li Q, Zou R, Shen J, Fang W, Tan G, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial. JAMA Oncol. 2019;5:953\u201360.","journal-title":"JAMA Oncol"},{"key":"3992_CR27","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.bbrc.2023.05.124","volume":"671","author":"X Da","year":"2023","unstructured":"Da X, Mo J, Li Q, Cao B, Huang J, Lu Y, et al. Targeted co-delivery of PD-L1 monoclonal antibody and sorafenib to circulating tumor cells via platelet-functionalized nanocarriers. Biochem Biophys Res Commun. 2023;671:335\u201342.","journal-title":"Biochem Biophys Res Commun"},{"key":"3992_CR28","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/17425247.2024.2440618","volume":"22","author":"H Mazumdar","year":"2025","unstructured":"Mazumdar H, Khondakar KR, Das S, Halder A, Kaushik A. Artificial intelligence for personalized nanomedicine; from material selection to patient outcomes. Expert Opin Drug Deliv. 2025;22:85\u2013108.","journal-title":"Expert Opin Drug Deliv"},{"key":"3992_CR29","doi-asserted-by":"publisher","first-page":"14213","DOI":"10.1039\/D4NR01832J","volume":"16","author":"J Wang","year":"2024","unstructured":"Wang J, Liu G, Zhou C, Cui X, Wang W, Wang J, et al. Application of artificial intelligence in cancer diagnosis and tumor nanomedicine. Nanoscale. 2024;16:14213\u201346.","journal-title":"Nanoscale"},{"key":"3992_CR30","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/hep.510280111","volume":"28","author":"R Yamaguchi","year":"1998","unstructured":"Yamaguchi R, Yano H, Iemura A, Ogasawara S, Haramaki M, Kojiro M. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology. 1998;28:68\u201377.","journal-title":"Hepatology"},{"key":"3992_CR31","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.1038\/sj.onc.1210121","volume":"26","author":"A Fischer","year":"2007","unstructured":"Fischer A, Fuchs E, Mikula M, Huber H, Beug H, Mikulits W. PDGF essentially links TGF-\u03b2 signaling to nuclear \u03b2-catenin accumulation in hepatocellular carcinoma progression. Oncogene. 2007;26:3395\u2013405.","journal-title":"Oncogene"},{"key":"3992_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061360","author":"Y Wang","year":"2021","unstructured":"Wang Y, Liu D, Zhang T, Xia L. FGF\/FGFR signaling in hepatocellular carcinoma: from carcinogenesis to recent therapeutic intervention. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13061360.","journal-title":"Cancers (Basel)"},{"key":"3992_CR33","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nrd.2018.21","volume":"17","author":"FM Ferguson","year":"2018","unstructured":"Ferguson FM, Gray NS. Kinase inhibitors: the road ahead. Nat Rev Drug Discov. 2018;17:353\u201377.","journal-title":"Nat Rev Drug Discov"},{"key":"3992_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-0187-x","volume":"5","author":"W Tang","year":"2020","unstructured":"Tang W, Chen Z, Zhang W, Cheng Y, Zhang B, Wu F, et al. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduct Target Ther. 2020;5:87.","journal-title":"Signal Transduct Target Ther"},{"key":"3992_CR35","doi-asserted-by":"publisher","first-page":"7879","DOI":"10.3892\/mmr.2017.7641","volume":"16","author":"H-Z Ying","year":"2017","unstructured":"Ying H-Z, Chen Q, Zhang W-Y, Zhang H-H, Ma Y, Zhang S-Z, et al. PDGF signaling pathway in hepatic fibrosis pathogenesis and therapeutics. Mol Med Rep. 2017;16:7879\u201389.","journal-title":"Mol Med Rep"},{"key":"3992_CR36","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1002\/hep.27968","volume":"62","author":"C Won","year":"2015","unstructured":"Won C, Kim BH, Yi EH, Choi KJ, Kim EK, Jeong JM, et al. Signal transducer and activator of transcription 3-mediated CD133 up-regulation contributes to promotion of hepatocellular carcinoma. Hepatology. 2015;62:1160\u201373.","journal-title":"Hepatology"},{"key":"3992_CR37","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/aps.2017.5","volume":"38","author":"Y-j Zhu","year":"2017","unstructured":"Zhu Y-j, Zheng B, Wang H-y, Chen L. New knowledge of the mechanisms of sorafenib resistance in liver cancer. Acta Pharmacol Sin. 2017;38:614\u201322.","journal-title":"Acta Pharmacol Sin"},{"key":"3992_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-019-0718-5","volume":"12","author":"S Qin","year":"2019","unstructured":"Qin S, Li A, Yi M, Yu S, Zhang M, Wu K. Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. J Hematol Oncol. 2019;12:1\u201311.","journal-title":"J Hematol Oncol"},{"key":"3992_CR39","first-page":"2051","volume":"52","author":"H Wang","year":"2018","unstructured":"Wang H, Zhang C, Chi H, Meng Z. Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR\/VEGF signaling. Int J Oncol. 2018;52:2051\u201360.","journal-title":"Int J Oncol"},{"key":"3992_CR40","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S285726","author":"F Fornari","year":"2021","unstructured":"Fornari F, Giovannini C, Piscaglia F, Gramantieri L. Elucidating the molecular basis of sorafenib resistance in HCC: current findings and future directions. J Hepatocell Carcinoma. 2021. https:\/\/doi.org\/10.2147\/JHC.S285726.","journal-title":"J Hepatocell Carcinoma"},{"key":"3992_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.102610","author":"S Xia","year":"2020","unstructured":"Xia S, Pan Y, Liang Y, Xu J, Cai X. The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma. EBioMedicine. 2020. https:\/\/doi.org\/10.1016\/j.ebiom.2019.102610.","journal-title":"EBioMedicine"},{"key":"3992_CR42","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1093\/carcin\/bgy038","volume":"39","author":"L Rosenberg","year":"2018","unstructured":"Rosenberg L, Yoon CH, Sharma G, Bertagnolli MM, Cho NL. Sorafenib inhibits proliferation and invasion in desmoid-derived cells by targeting Ras\/MEK\/ERK and PI3K\/Akt\/mTOR pathways. Carcinogenesis. 2018;39:681\u20138.","journal-title":"Carcinogenesis"},{"key":"3992_CR43","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/hep.30190","volume":"69","author":"MA Ardelt","year":"2019","unstructured":"Ardelt MA, Fr\u00f6hlich T, Martini E, M\u00fcller M, Kanitz V, Atzberger C, et al. Inhibition of cyclin-dependent kinase 5: a strategy to improve sorafenib response in hepatocellular carcinoma therapy. Hepatology. 2019;69:376\u201393.","journal-title":"Hepatology"},{"key":"3992_CR44","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.7150\/thno.25487","volume":"8","author":"CX Wu","year":"2018","unstructured":"Wu CX, Wang XQ, Chok SH, Man K, Tsang SHY, Chan ACY, et al. Blocking CDK1\/PDK1\/\u03b2-catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinoma. Theranostics. 2018;8:3737.","journal-title":"Theranostics"},{"key":"3992_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.envres.2023.115683","volume":"227","author":"YE Alqurashi","year":"2023","unstructured":"Alqurashi YE, Al-Hetty HRAK, Ramaiah P, Fazaa AH, Jalil AT, Alsaikhan F, et al. Harnessing function of EMT in hepatocellular carcinoma: from biological view to nanotechnological standpoint. Environ Res. 2023;227:115683.","journal-title":"Environ Res"},{"key":"3992_CR46","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.jhep.2016.05.007","volume":"65","author":"G Giannelli","year":"2016","unstructured":"Giannelli G, Koudelkova P, Dituri F, Mikulits W. Role of epithelial to mesenchymal transition in hepatocellular carcinoma. J Hepatol. 2016;65:798\u2013808.","journal-title":"J Hepatol"},{"key":"3992_CR47","volume":"2014","author":"W Chen","year":"2014","unstructured":"Chen W, Wu J, Shi H, Wang Z, Zhang G, Cao Y, et al. Hepatic stellate cell coculture enables sorafenib resistance in Huh7 cells through HGF\/c\u2010Met\/Akt and Jak2\/Stat3 pathways. Biomed Res Int. 2014;2014:764981.","journal-title":"Biomed Res Int"},{"key":"3992_CR48","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/hepr.13445","volume":"50","author":"T Minagawa","year":"2020","unstructured":"Minagawa T, Yamazaki K, Masugi Y, Tsujikawa H, Ojima H, Hibi T, et al. Activation of extracellular signal-regulated kinase is associated with hepatocellular carcinoma with aggressive phenotypes. Hepatol Res. 2020;50:353\u201364.","journal-title":"Hepatol Res"},{"key":"3992_CR49","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1002\/hep.29496","volume":"67","author":"M Bouattour","year":"2018","unstructured":"Bouattour M, Raymond E, Qin S, Cheng AL, Stammberger U, Locatelli G, et al. Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma. Hepatology. 2018;67:1132\u201349.","journal-title":"Hepatology"},{"key":"3992_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.601240","volume":"10","author":"C Donisi","year":"2021","unstructured":"Donisi C, Puzzoni M, Ziranu P, Lai E, Mariani S, Saba G, et al. Immune checkpoint inhibitors in the treatment of HCC. Front Oncol. 2021;10:601240.","journal-title":"Front Oncol"},{"key":"3992_CR51","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/nrgastro.2015.173","volume":"12","author":"J Prieto","year":"2015","unstructured":"Prieto J, Melero I, Sangro B. Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2015;12:681\u2013700.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3992_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-40078-8","volume":"9","author":"HL Lee","year":"2019","unstructured":"Lee HL, Jang JW, Lee SW, Yoo SH, Kwon JH, Nam SW, et al. Inflammatory cytokines and change of Th1\/Th2 balance as prognostic indicators for hepatocellular carcinoma in patients treated with transarterial chemoembolization. Sci Rep. 2019;9:3260.","journal-title":"Sci Rep"},{"key":"3992_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41421-023-00529-z","volume":"9","author":"G-Q Zhu","year":"2023","unstructured":"Zhu G-Q, Tang Z, Huang R, Qu W-F, Fang Y, Yang R, et al. CD36+ cancer-associated fibroblasts provide immunosuppressive microenvironment for hepatocellular carcinoma via secretion of macrophage migration inhibitory factor. Cell Discov. 2023;9:25.","journal-title":"Cell Discov"},{"key":"3992_CR54","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.canlet.2019.05.019","volume":"458","author":"Z Li","year":"2019","unstructured":"Li Z, Wu T, Zheng B, Chen L. Individualized precision treatment: targeting TAM in HCC. Cancer Lett. 2019;458:86\u201391.","journal-title":"Cancer Lett"},{"key":"3992_CR55","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1021\/acscentsci.9b01235","volume":"6","author":"H Xiao","year":"2020","unstructured":"Xiao H, Guo Y, Li B, Li X, Wang Y, Han S, et al. M2-like tumor-associated macrophage-targeted codelivery of STAT6 inhibitor and IKK\u03b2 siRNA induces M2-to-M1 repolarization for cancer immunotherapy with low immune side effects. ACS Cent Sci. 2020;6:1208\u201322.","journal-title":"ACS Cent Sci"},{"key":"3992_CR56","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1002\/hep.26328","volume":"57","author":"MF Sprinzl","year":"2013","unstructured":"Sprinzl MF, Reisinger F, Puschnik A, Ringelhan M, Ackermann K, Hartmann D, et al. Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells. Hepatology. 2013;57:2358\u201368.","journal-title":"Hepatology"},{"key":"3992_CR57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055945","volume":"8","author":"Q-B Zhang","year":"2013","unstructured":"Zhang Q-B, Sun H-C, Zhang K-Z, Jia Q-A, Bu Y, Wang M, et al. Suppression of natural killer cells by sorafenib contributes to prometastatic effects in hepatocellular carcinoma. PLoS ONE. 2013;8:e55945.","journal-title":"PLoS ONE"},{"key":"3992_CR58","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2024.14501","volume":"28","author":"X Kang","year":"2024","unstructured":"Kang X, Zhao S, Lin S, Li J, Wang S. Synergistic upregulation of PD\u2011L1 in tumor cells and CD39 in tumor\u2011infiltrating CD8+ T cells leads to poor prognosis in patients with hepatocellular carcinoma. Oncol Lett. 2024;28:368.","journal-title":"Oncol Lett"},{"key":"3992_CR59","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1007\/s12032-010-9515-2","volume":"28","author":"C-Y Mu","year":"2011","unstructured":"Mu C-Y, Huang J-A, Chen Y, Chen C, Zhang X-G. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol. 2011;28:682\u20138.","journal-title":"Med Oncol"},{"key":"3992_CR60","doi-asserted-by":"publisher","first-page":"5127","DOI":"10.1007\/s00432-022-04458-4","volume":"149","author":"J Wang","year":"2023","unstructured":"Wang J, Hu F, Yu P, Wang J, Liu Z, Bao Q, et al. Sorafenib inhibits doxorubicin-induced PD-L1 upregulation to improve immunosuppressive microenvironment in osteosarcoma. J Cancer Res Clin Oncol. 2023;149:5127\u201338.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3992_CR61","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1146\/annurev-pathol-052016-100322","volume":"12","author":"S Affo","year":"2017","unstructured":"Affo S, Yu L-X, Schwabe RF. The role of cancer-associated fibroblasts and fibrosis in liver cancer. Annu Rev Pathol Mech Dis. 2017;12:153\u201386.","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"3992_CR62","doi-asserted-by":"publisher","first-page":"4128","DOI":"10.3748\/wjg.v20.i15.4128","volume":"20","author":"B Rani","year":"2014","unstructured":"Rani B, Cao Y, Malfettone A, Tomuleasa C, Fabregat I, Giannelli G. Role of the tissue microenvironment as a therapeutic target in hepatocellular carcinoma. World J Gastroenterol. 2014;20:4128.","journal-title":"World J Gastroenterol"},{"key":"3992_CR63","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/s41388-021-02171-z","volume":"41","author":"B Chiavarina","year":"2022","unstructured":"Chiavarina B, Ronca R, Otaka Y, Sutton RB, Rezzola S, Yokobori T, et al. Fibroblast-derived prolargin is a tumor suppressor in hepatocellular carcinoma. Oncogene. 2022;41:1410\u201320.","journal-title":"Oncogene"},{"key":"3992_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/cells9092027","volume":"9","author":"L Kaps","year":"2020","unstructured":"Kaps L, Schuppan D. Targeting cancer associated fibroblasts in liver fibrosis and liver cancer using nanocarriers. Cells. 2020;9:2027.","journal-title":"Cells"},{"key":"3992_CR65","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.bcp.2018.04.014","volume":"154","author":"C-L Chung","year":"2018","unstructured":"Chung C-L, Wang S-W, Sun W-C, Shu C-W, Kao Y-C, Shiao M-S, et al. Sorafenib suppresses TGF-\u03b2 responses by inducing caveolae\/lipid raft-mediated internalization\/degradation of cell-surface type II TGF-\u03b2 receptors: implications in development of effective adjunctive therapy for hepatocellular carcinoma. Biochem Pharmacol. 2018;154:39\u201353.","journal-title":"Biochem Pharmacol"},{"key":"3992_CR66","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/j.jhep.2015.02.038","volume":"62","author":"OV Makarova-Rusher","year":"2015","unstructured":"Makarova-Rusher OV, Medina-Echeverz J, Duffy AG, Greten TF. The yin and yang of evasion and immune activation in HCC. J Hepatol. 2015;62:1420\u20139.","journal-title":"J Hepatol"},{"key":"3992_CR67","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jhep.2023.03.003","volume":"79","author":"L Rimassa","year":"2023","unstructured":"Rimassa L, Finn RS, Sangro B. Combination immunotherapy for hepatocellular carcinoma. J Hepatol. 2023;79:506\u201315.","journal-title":"J Hepatol"},{"key":"3992_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.963031","volume":"13","author":"H Sun","year":"2022","unstructured":"Sun H, Xing C, Jiang S, Yu K, Dai S, Kong H, et al. Long term complete response of advanced hepatocellular carcinoma to glypican-3 specific chimeric antigen receptor T-Cells plus sorafenib, a case report. Front Immunol. 2022;13:963031.","journal-title":"Front Immunol"},{"key":"3992_CR69","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3892\/mco.2016.925","volume":"5","author":"Y Yi","year":"2016","unstructured":"Yi Y, Han J, Fang Y, Liu D, Wu Z, Wang L, et al. Sorafenib and a novel immune therapy in lung metastasis from hepatocellular carcinoma following hepatectomy: a case report. Mol Clin Oncol. 2016;5:337\u201341.","journal-title":"Mol Clin Oncol"},{"key":"3992_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioadv.2022.212761","volume":"136","author":"Z Li","year":"2022","unstructured":"Li Z, Bu J, Zhu X, Zhou H, Ren K, Chu PK, et al. Anti-tumor immunity and ferroptosis of hepatocellular carcinoma are enhanced by combined therapy of sorafenib and delivering modified GO-based PD-L1 siRNAs. Biomaterials Advances. 2022;136:212761.","journal-title":"Biomaterials Advances"},{"key":"3992_CR71","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.ijpharm.2011.08.003","volume":"419","author":"X-q Wang","year":"2011","unstructured":"Wang X-q, Fan J-m, Liu Y-o, Zhao B, Jia Z-r, Zhang Q. bioavailability and pharmacokinetics of sorafenib suspension, nanoparticles and nanomatrix for oral administration to rat. Int J Pharm. 2011;419:339\u201346.","journal-title":"Int J Pharm"},{"key":"3992_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.plipres.2017.07.001","volume":"68","author":"M Teixeira","year":"2017","unstructured":"Teixeira M, Carbone C, Souto E. Beyond liposomes: recent advances on lipid based nanostructures for poorly soluble\/poorly permeable drug delivery. Prog Lipid Res. 2017;68:1\u201311.","journal-title":"Prog Lipid Res"},{"key":"3992_CR73","doi-asserted-by":"publisher","DOI":"10.2147\/ijn.s415968","author":"TM Caputo","year":"2023","unstructured":"Caputo TM, Cusano AM, Principe S, Cicatiello P, Celetti G, Aliberti A, et al. Sorafenib-loaded PLGA carriers for enhanced drug delivery and cellular uptake in liver cancer cells. Int J Nanomedicine. 2023. https:\/\/doi.org\/10.2147\/ijn.s415968.","journal-title":"Int J Nanomedicine"},{"key":"3992_CR74","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S223941","author":"RS Darweesh","year":"2019","unstructured":"Darweesh RS, Ayoub NM, Nazzal S. Gold nanoparticles and angiogenesis: molecular mechanisms and biomedical applications. Int J Nanomedicine. 2019. https:\/\/doi.org\/10.2147\/IJN.S223941.","journal-title":"Int J Nanomedicine"},{"key":"3992_CR75","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1007\/s13346-020-00780-x","volume":"10","author":"Y Chu","year":"2020","unstructured":"Chu Y, Zhang J, Pan H, Shi J, Wang J, Chen L. Preparation and evaluation of long circulating erythrocyte membrane-cloaked anti-cancer drug delivery system. Drug Deliv Transl Res. 2020;10:1278\u201387.","journal-title":"Drug Deliv Transl Res"},{"key":"3992_CR76","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202204335","volume":"9","author":"M Yu","year":"2022","unstructured":"Yu M, Yang W, Yue W, Chen Y. Targeted cancer immunotherapy: nanoformulation engineering and clinical translation. Adv Sci. 2022;9:2204335.","journal-title":"Adv Sci"},{"key":"3992_CR77","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1039\/C2RA22093H","volume":"3","author":"M Ghavami","year":"2013","unstructured":"Ghavami M, Saffar S, Abd Emamy B, Peirovi A, Shokrgozar MA, Serpooshan V, et al. Plasma concentration gradient influences the protein corona decoration on nanoparticles. RSC Adv. 2013;3:1119\u201326.","journal-title":"RSC Adv"},{"key":"3992_CR78","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1039\/C6RA25493D","volume":"7","author":"A Amici","year":"2017","unstructured":"Amici A, Caracciolo G, Digiacomo L, Gambini V, Marchini C, Tilio M, et al. In vivo protein corona patterns of lipid nanoparticles. RSC Adv. 2017;7:1137\u201345.","journal-title":"RSC Adv"},{"key":"3992_CR79","doi-asserted-by":"publisher","first-page":"6948","DOI":"10.1039\/C5NR09158F","volume":"8","author":"M Hadjidemetriou","year":"2016","unstructured":"Hadjidemetriou M, Al-Ahmady Z, Kostarelos K. Time-evolution of in vivo protein corona onto blood-circulating PEGylated liposomal doxorubicin (DOXIL) nanoparticles. Nanoscale. 2016;8:6948\u201357.","journal-title":"Nanoscale"},{"key":"3992_CR80","doi-asserted-by":"publisher","first-page":"7331","DOI":"10.1021\/acsnano.1c08508","volume":"16","author":"K-R Kim","year":"2022","unstructured":"Kim K-R, Kim J, Back JH, Lee JE, Ahn D-R. Cholesterol-mediated seeding of protein corona on DNA nanostructures for targeted delivery of oligonucleotide therapeutics to treat liver fibrosis. ACS Nano. 2022;16:7331\u201343.","journal-title":"ACS Nano"},{"key":"3992_CR81","doi-asserted-by":"publisher","first-page":"5397","DOI":"10.1039\/D0CS01127D","volume":"50","author":"MS de Almeida","year":"2021","unstructured":"de Almeida MS, Susnik E, Drasler B, Taladriz-Blanco P, Petri-Fink A, Rothen-Rutishauser B. Understanding nanoparticle endocytosis to improve targeting strategies in nanomedicine. Chem Soc Rev. 2021;50:5397\u2013434.","journal-title":"Chem Soc Rev"},{"key":"3992_CR82","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jconrel.2010.01.036","volume":"145","author":"G Sahay","year":"2010","unstructured":"Sahay G, Alakhova DY, Kabanov AV. Endocytosis of nanomedicines. J Control Release. 2010;145:182\u201395.","journal-title":"J Control Release"},{"key":"3992_CR83","doi-asserted-by":"publisher","first-page":"9138","DOI":"10.1021\/la401556k","volume":"29","author":"X Liu","year":"2013","unstructured":"Liu X, Huang N, Li H, Jin Q, Ji J. Surface and size effects on cell interaction of gold nanoparticles with both phagocytic and nonphagocytic cells. Langmuir. 2013;29:9138\u201348.","journal-title":"Langmuir"},{"key":"3992_CR84","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0205765","volume":"13","author":"Y Bouallegui","year":"2018","unstructured":"Bouallegui Y, Ben Younes R, Oueslati R, Sheehan D. Redox proteomic insights into involvement of clathrin-mediated endocytosis in silver nanoparticles toxicity to Mytilus galloprovincialis. PLoS One. 2018;13:e0205765.","journal-title":"PLoS One"},{"key":"3992_CR85","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.apsb.2020.11.020","volume":"11","author":"C Yang","year":"2021","unstructured":"Yang C, He B, Dai W, Zhang H, Zheng Y, Wang X, et al. The role of caveolin-1 in the biofate and efficacy of anti-tumor drugs and their nano-drug delivery systems. Acta Pharm Sin B. 2021;11:961\u201377.","journal-title":"Acta Pharm Sin B"},{"key":"3992_CR86","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.jconrel.2021.04.001","volume":"333","author":"Y Wang","year":"2021","unstructured":"Wang Y, Zhang H, Xiao W, Liu Y, Zhou Y, He X, et al. Unmasking CSF protein corona: effect on targeting capacity of nanoparticles. J Control Release. 2021;333:352\u201361.","journal-title":"J Control Release"},{"key":"3992_CR87","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1080\/10717544.2016.1225856","volume":"24","author":"S Pranatharthiharan","year":"2017","unstructured":"Pranatharthiharan S, Patel MD, Malshe VC, Pujari V, Gorakshakar A, Madkaikar M, et al. Asialoglycoprotein receptor targeted delivery of doxorubicin nanoparticles for hepatocellular carcinoma. Drug Deliv. 2017;24:20\u20139.","journal-title":"Drug Deliv"},{"key":"3992_CR88","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/sj.bjc.6690708","volume":"81","author":"D Trere","year":"1999","unstructured":"Trere D, Fiume L, Giorgi L, Di Stefano G, Migaldi M, Derenzini M. The asialoglycoprotein receptor in human hepatocellular carcinomas: its expression on proliferating cells. Br J Cancer. 1999;81:404\u20138.","journal-title":"Br J Cancer"},{"key":"3992_CR89","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/978-3-7091-1065-2_33","volume-title":"Animal Lectins: Form, Function and Clinical Applications","author":"G Gupta","year":"2012","unstructured":"Gupta G, Gupta A. Asialoglycoprotein receptor and the macrophage galactose-type lectin. In: Animal Lectins: Form, Function and Clinical Applications. 2012. p. 709\u201324."},{"key":"3992_CR90","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1021\/acs.biomac.7b00228","volume":"18","author":"J Tanaka","year":"2017","unstructured":"Tanaka J, Gleinich AS, Zhang Q, Whitfield R, Kempe K, Haddleton DM, et al. Specific and differential binding of N-acetylgalactosamine glycopolymers to the human macrophage galactose lectin and asialoglycoprotein receptor. Biomacromol. 2017;18:1624\u201333.","journal-title":"Biomacromol"},{"key":"3992_CR91","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.2217\/nnm.15.43","volume":"10","author":"J Jiang","year":"2015","unstructured":"Jiang J, Chen H, Yu C, Zhang Y, Chen M, Tian S, et al. The promotion of salinomycin delivery to hepatocellular carcinoma cells through EGFR and CD133 aptamers conjugation by PLGA nanoparticles. Nanomedicine. 2015;10:1863\u201379.","journal-title":"Nanomedicine"},{"key":"3992_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116183","volume":"267","author":"X Zhang","year":"2024","unstructured":"Zhang X, Chen Y, Li X, Xu H, Yang J, Wang C, et al. Carrier-free self-assembled nanomedicine based on celastrol and galactose for targeting therapy of hepatocellular carcinoma via inducing ferroptosis. Eur J Med Chem. 2024;267:116183.","journal-title":"Eur J Med Chem"},{"key":"3992_CR93","doi-asserted-by":"publisher","first-page":"5019","DOI":"10.1021\/acs.molpharmaceut.8b00612","volume":"15","author":"G Su","year":"2018","unstructured":"Su G, Jiang H, Xu B, Yu Y, Chen X. Effects of protein corona on active and passive targeting of cyclic RGD peptide-functionalized PEGylation nanoparticles. Mol Pharm. 2018;15:5019\u201330.","journal-title":"Mol Pharm"},{"key":"3992_CR94","doi-asserted-by":"publisher","first-page":"2408039","DOI":"10.1002\/smll.202408039","volume":"21","author":"J Hammond","year":"2025","unstructured":"Hammond J, Richards CJ, Ko Y, Jonker T, \u00c5berg C, Roos WH, et al. Membrane fusion-based drug delivery liposomes transiently modify the material properties of synthetic and biological membranes. Small. 2025;21:2408039.","journal-title":"Small"},{"key":"3992_CR95","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202400219","volume":"13","author":"N Jia","year":"2024","unstructured":"Jia N, Wang Q, Li W, Chen D, Hu H. Membrane fusion liposomes deliver antifibrotic and chemotherapeutic drugs sequentially to enhance tumor treatment efficacy by reshaping tumor microenvironment. Adv Healthc Mater. 2024;13:2400219.","journal-title":"Adv Healthc Mater"},{"key":"3992_CR96","doi-asserted-by":"publisher","first-page":"2207125","DOI":"10.1002\/smll.202207125","volume":"19","author":"E Canepa","year":"2023","unstructured":"Canepa E, Bochicchio D, Brosio G, Silva PHJ, Stellacci F, Dante S, et al. Cholesterol-containing liposomes decorated with Au nanoparticles as minimal tunable fusion machinery. Small. 2023;19:2207125.","journal-title":"Small"},{"key":"3992_CR97","doi-asserted-by":"publisher","first-page":"7333","DOI":"10.1158\/1078-0432.CCR-17-0950","volume":"23","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan M, Xing D, Luan L, Xu H, Sharma RB, Popovic A, et al. Characterization of the immune microenvironment in hepatocellular carcinoma. Clin Cancer Res. 2017;23:7333\u20139.","journal-title":"Clin Cancer Res"},{"key":"3992_CR98","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s12072-020-10104-3","volume":"14","author":"C Santhakumar","year":"2020","unstructured":"Santhakumar C, Gane EJ, Liu K, McCaughan GW. Current perspectives on the tumor microenvironment in hepatocellular carcinoma. Hepatol Int. 2020;14:947\u201357.","journal-title":"Hepatol Int"},{"key":"3992_CR99","doi-asserted-by":"publisher","first-page":"65131","DOI":"10.1021\/acsami.4c11076","volume":"16","author":"Y Wu","year":"2024","unstructured":"Wu Y, Wang X, Li L, Wang M, Tian S, Song J, et al. Preparation of glutathione-regulated sorafenib targeted nanodrug delivery system and its antihepatocellular carcinoma activity. ACS Appl Mater Interfaces. 2024;16:65131\u201341.","journal-title":"ACS Appl Mater Interfaces"},{"key":"3992_CR100","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1021\/acs.biomac.3c01173","volume":"25","author":"S Liu","year":"2023","unstructured":"Liu S, Liu Y, Chang Q, Celia C, Deng X, Xie Y. pH-responsive sorafenib\/iron-co-loaded mesoporous polydopamine nanoparticles for synergistic ferroptosis and photothermal therapy. Biomacromol. 2023;25:522\u201331.","journal-title":"Biomacromol"},{"key":"3992_CR101","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061576","volume":"12","author":"LKD Cabral","year":"2020","unstructured":"Cabral LKD, Tiribelli C, Sukowati CH. Sorafenib resistance in hepatocellular carcinoma: the relevance of genetic heterogeneity. Cancers. 2020;12:1576.","journal-title":"Cancers"},{"key":"3992_CR102","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.991052","volume":"13","author":"X Tian","year":"2022","unstructured":"Tian X, Yan T, Liu F, Liu Q, Zhao J, Xiong H, et al. Link of sorafenib resistance with the tumor microenvironment in hepatocellular carcinoma: mechanistic insights. Front Pharmacol. 2022;13:991052.","journal-title":"Front Pharmacol"},{"key":"3992_CR103","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1156383","volume":"11","author":"K Zhang","year":"2023","unstructured":"Zhang K, Zhang Q, Jia R, Xiang S, Xu L. A comprehensive review of the relationship between autophagy and sorafenib-resistance in hepatocellular carcinoma: ferroptosis is noteworthy. Front Cell Dev Biol. 2023;11:1156383.","journal-title":"Front Cell Dev Biol"},{"key":"3992_CR104","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201803335","volume":"31","author":"M Hadjidemetriou","year":"2019","unstructured":"Hadjidemetriou M, McAdam S, Garner G, Thackeray C, Knight D, Smith D, et al. The human in vivo biomolecule corona onto PEGylated liposomes: a proof\u2010of\u2010concept clinical study. Adv Mater. 2019;31:1803335.","journal-title":"Adv Mater"},{"key":"3992_CR105","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S109059","author":"C Corbo","year":"2016","unstructured":"Corbo C, Molinaro R, Taraballi F, Toledano Furman NE, Sherman MB, Parodi A, et al. Effects of the protein corona on liposome\u2013liposome and liposome\u2013cell interactions. Int J Nanomedicine. 2016. https:\/\/doi.org\/10.2147\/IJN.S109059.","journal-title":"Int J Nanomedicine"},{"key":"3992_CR106","doi-asserted-by":"publisher","first-page":"4434","DOI":"10.1039\/D4NA00345D","volume":"6","author":"E Imperlini","year":"2024","unstructured":"Imperlini E, Di Marzio L, Cevenini A, Costanzo M, d\u2019Avanzo N, Fresta M, et al. Unraveling the impact of different liposomal formulations on the plasma protein corona composition might give hints on the targeting capability of nanoparticles. Nanoscale Adv. 2024;6:4434\u201349.","journal-title":"Nanoscale Adv"},{"key":"3992_CR107","doi-asserted-by":"publisher","DOI":"10.3390\/nano14100823","volume":"14","author":"B \u00d6nal Acet","year":"2024","unstructured":"\u00d6nal Acet B, G\u00fcl D, Stauber RH, Odaba\u015f\u0131 M, Acet \u00d6. A review for uncovering the \u201cprotein-nanoparticle alliance\u201d: implications of the protein corona for biomedical applications. Nanomaterials. 2024;14:823.","journal-title":"Nanomaterials"},{"key":"3992_CR108","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S33803","author":"M Ekkapongpisit","year":"2012","unstructured":"Ekkapongpisit M, Giovia A, Follo C, Caputo G, Isidoro C. Biocompatibility, endocytosis, and intracellular trafficking of mesoporous silica and polystyrene nanoparticles in ovarian cancer cells: effects of size and surface charge groups. Int J Nanomedicine. 2012. https:\/\/doi.org\/10.2147\/IJN.S33803.","journal-title":"Int J Nanomedicine"},{"key":"3992_CR109","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-26979-1","volume":"13","author":"PM Perrigue","year":"2023","unstructured":"Perrigue PM, Henschke A, Grze\u015bkowiak BF, Przysiecka \u0141, Jaskot K, Mielcarek A, et al. Cellular uptake and retention studies of silica nanoparticles utilizing senescent fibroblasts. Sci Rep. 2023;13:475.","journal-title":"Sci Rep"},{"key":"3992_CR110","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.3390\/cancers13123076","volume":"13","author":"Y-T Lee","year":"2021","unstructured":"Lee Y-T, Tran BV, Wang JJ, Liang IY, You S, Zhu Y, et al. The role of extracellular vesicles in disease progression and detection of hepatocellular carcinoma. Cancers. 2021;13:3076.","journal-title":"Cancers"},{"key":"3992_CR111","doi-asserted-by":"publisher","first-page":"283","DOI":"10.20517\/evcna.2023.26","volume":"4","author":"L Ribovski","year":"2023","unstructured":"Ribovski L, Joshi B, Gao J, Zuhorn I. Breaking free: endocytosis and endosomal escape of extracellular vesicles. Extracell Vesicles Circ Nucleic Acids. 2023;4:283.","journal-title":"Extracell Vesicles Circ Nucleic Acids"},{"key":"3992_CR112","first-page":"5573","volume":"11","author":"A Li","year":"2019","unstructured":"Li A, Zhang R, Zhang Y, Liu X, Wang R, Liu J, et al. BEZ235 increases sorafenib inhibition of hepatocellular carcinoma cells by suppressing the PI3K\/AKT\/mTOR pathway. Am J Transl Res. 2019;11:5573.","journal-title":"Am J Transl Res"},{"key":"3992_CR113","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1080\/17425247.2020.1730809","volume":"17","author":"B Wu","year":"2020","unstructured":"Wu B, Li A, Zhang Y, Liu X, Zhou S, Gan H, et al. Resistance of hepatocellular carcinoma to sorafenib can be overcome with co-delivery of PI3K\/mTOR inhibitor BEZ235 and sorafenib in nanoparticles. Expert Opin Drug Deliv. 2020;17:573\u201387.","journal-title":"Expert Opin Drug Deliv"},{"key":"3992_CR114","doi-asserted-by":"publisher","first-page":"44123","DOI":"10.1038\/srep44123","volume":"7","author":"Y Chen","year":"2017","unstructured":"Chen Y, Liu Y-C, Sung Y-C, Ramjiawan RR, Lin T-T, Chang C-C, et al. Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors. Sci Rep. 2017;7:44123.","journal-title":"Sci Rep"},{"key":"3992_CR115","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jconrel.2021.01.021","volume":"331","author":"MA Younis","year":"2021","unstructured":"Younis MA, Khalil IA, Elewa YHA, Kon Y, Harashima H. Ultra-small lipid nanoparticles encapsulating sorafenib and midkine-siRNA selectively-eradicate sorafenib-resistant hepatocellular carcinoma in vivo. J Control Release. 2021;331:335\u201349.","journal-title":"J Control Release"},{"key":"3992_CR116","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/1351046","volume":"2020","author":"H Ye","year":"2020","unstructured":"Ye H, Zhou L, Jin H, Chen Y, Cheng D, Jiang Y. Sorafenib\u2010loaded long\u2010circulating nanoliposomes for liver cancer therapy. Biomed Res Int. 2020;2020:1351046.","journal-title":"Biomed Res Int"},{"key":"3992_CR117","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1211\/jpp.59.4.0001","volume":"59","author":"H Karanth","year":"2007","unstructured":"Karanth H, Murthy RSR. pH-sensitive liposomes-principle and application in cancer therapy. J Pharm Pharmacol. 2007;59:469\u201383.","journal-title":"J Pharm Pharmacol"},{"key":"3992_CR118","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.colsurfb.2016.01.016","volume":"141","author":"Y Xiao","year":"2016","unstructured":"Xiao Y, Liu Y, Yang S, Zhang B, Wang T, Jiang D, et al. Sorafenib and gadolinium co-loaded liposomes for drug delivery and MRI-guided HCC treatment. Colloids Surf B Biointerfaces. 2016;141:83\u201392.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"3992_CR119","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0939-6411(00)00087-4","volume":"50","author":"RH M\u00fcller","year":"2000","unstructured":"M\u00fcller RH, M\u00e4der K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery\u2013a review of the state of the art. Eur J Pharm Biopharm. 2000;50:161\u201377.","journal-title":"Eur J Pharm Biopharm"},{"key":"3992_CR120","first-page":"7","volume":"3","author":"I Yahya","year":"2019","unstructured":"Yahya I, Atif R, Ahmed L, Eldeen TS, Omara A, Eltayeb M. Utilization of solid lipid nanoparticles loaded anticancer agents as drug delivery systems for controlled release. Int J Eng Appl Sci Technol. 2019;3:7\u201316.","journal-title":"Int J Eng Appl Sci Technol"},{"key":"3992_CR121","doi-asserted-by":"publisher","first-page":"831","DOI":"10.3390\/pharmaceutics15030831","volume":"15","author":"J German-Cort\u00e9s","year":"2023","unstructured":"German-Cort\u00e9s J, Vilar-Hern\u00e1ndez M, Rafael D, Abasolo I, Andrade F. Solid lipid nanoparticles: multitasking nano-carriers for cancer treatment. Pharmaceutics. 2023;15:831.","journal-title":"Pharmaceutics"},{"key":"3992_CR122","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1021\/acs.bioconjchem.5b00590","volume":"27","author":"K Oumzil","year":"2016","unstructured":"Oumzil K, Ramin MA, Lorenzato C, H\u00e9madou A, Laroche J, Jacobin-Valat MJ, et al. Solid lipid nanoparticles for image-guided therapy of atherosclerosis. Bioconjug Chem. 2016;27:569\u201375.","journal-title":"Bioconjug Chem"},{"key":"3992_CR123","doi-asserted-by":"publisher","DOI":"10.1186\/s11671-017-2420-2","volume":"13","author":"S Benizri","year":"2018","unstructured":"Benizri S, Ferey L, Alies B, Mebarek N, Vacher G, Appavoo A, et al. Nucleoside-lipid-based nanocarriers for sorafenib delivery. Nanoscale Res Lett. 2018;13:17.","journal-title":"Nanoscale Res Lett"},{"key":"3992_CR124","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2025.140030","volume":"299","author":"NU Sahar","year":"2025","unstructured":"Sahar NU, Gul M, Choi HI, Ryu JS, Noh HY, Vo DK, et al. Lipid core-chitosan shell hybrid nanoparticles for enhanced oral bioavailability of sorafenib. Int J Biol Macromol. 2025;299:140030.","journal-title":"Int J Biol Macromol"},{"key":"3992_CR125","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1002\/adhm.201500235","volume":"4","author":"A Grillone","year":"2015","unstructured":"Grillone A, Riva ER, Mondini A, Forte C, Calucci L, Innocenti C, et al. Active targeting of sorafenib: preparation, characterization, and in vitro testing of drug-loaded magnetic solid lipid nanoparticles. Adv Healthc Mater. 2015;4:1681\u201390.","journal-title":"Adv Healthc Mater"},{"key":"3992_CR126","doi-asserted-by":"publisher","DOI":"10.1002\/anbr.202100109","volume":"2","author":"L Xu","year":"2022","unstructured":"Xu L, Wang X, Liu Y, Yang G, Falconer RJ, Zhao C-X. Lipid nanoparticles for drug delivery. Adv NanoBiomed Res. 2022;2:2100109.","journal-title":"Adv NanoBiomed Res"},{"key":"3992_CR127","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ijpharm.2015.07.055","volume":"493","author":"ML Bond\u00ec","year":"2015","unstructured":"Bond\u00ec ML, Botto C, Amore E, Emma MR, Augello G, Craparo EF, et al. Lipid nanocarriers containing sorafenib inhibit colonies formation in human hepatocarcinoma cells. Int J Pharm. 2015;493:75\u201385.","journal-title":"Int J Pharm"},{"key":"3992_CR128","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.jsps.2021.06.006","volume":"29","author":"B Wang","year":"2021","unstructured":"Wang B, Sun L, Wen M, Tan Y, Almalki WH, Katouah H, et al. Nano lipidic carriers for codelivery of sorafenib and ganoderic acid for enhanced synergistic antitumor efficacy against hepatocellular carcinoma. Saudi Pharm J. 2021;29:843\u201356.","journal-title":"Saudi Pharm J"},{"key":"3992_CR129","doi-asserted-by":"publisher","first-page":"6945","DOI":"10.2147\/IJN.S467876","volume":"19","author":"N Qu","year":"2024","unstructured":"Qu N, Ke S, Yating J, Mingxia L, Lijiang C, J. LR, et al. Albumin nanoparticle-based drug delivery systems. Int J Nanomedicine. 2024;19:6945\u201380.","journal-title":"Int J Nanomedicine"},{"key":"3992_CR130","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jconrel.2015.06.006","volume":"211","author":"M Bern","year":"2015","unstructured":"Bern M, Sand KMK, Nilsen J, Sandlie I, Andersen JT. The role of albumin receptors in regulation of albumin homeostasis: implications for drug delivery. J Control Release. 2015;211:144\u201362.","journal-title":"J Control Release"},{"key":"3992_CR131","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.jconrel.2011.11.028","volume":"161","author":"F Kratz","year":"2012","unstructured":"Kratz F, Elsadek B. Clinical impact of serum proteins on drug delivery. J Control Release. 2012;161:429\u201345.","journal-title":"J Control Release"},{"key":"3992_CR132","doi-asserted-by":"publisher","first-page":"5075","DOI":"10.1166\/jnn.2021.19362","volume":"21","author":"Y Ming","year":"2021","unstructured":"Ming Y, Li B, Fu R, Xing H, Liu Y, Duan D, et al. Bovine serum albumin nanoparticle-mediated delivery of sorafenib for improving hepatocellular carcinoma therapy. J Nanosci Nanotechnol. 2021;21:5075\u201382.","journal-title":"J Nanosci Nanotechnol"},{"key":"3992_CR133","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2022.103142","volume":"69","author":"L Dayani","year":"2022","unstructured":"Dayani L, Dehghani M, Aghaei M, Taymouri S, Taheri A. Preparation and evaluation of targeted albumin lipid nanoparticles with lactobionic acid for targeted drug delivery of sorafenib in hepatocellular carcinoma. J Drug Deliv Sci Technol. 2022;69:103142.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3992_CR134","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2019.117013","volume":"239","author":"Z Wang","year":"2019","unstructured":"Wang Z, Duan X, Lv Y, Zhao Y. Low density lipoprotein receptor (LDLR)-targeted lipid nanoparticles for the delivery of sorafenib and dihydroartemisinin in liver cancers. Life Sci. 2019;239:117013.","journal-title":"Life Sci"},{"key":"3992_CR135","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2023.126766","volume":"253","author":"D Wang","year":"2023","unstructured":"Wang D, Zhang Z, Zhao L, Yang L, Lou C. Recent advances in natural polysaccharides against hepatocellular carcinoma: a review. Int J Biol Macromol. 2023;253:126766.","journal-title":"Int J Biol Macromol"},{"key":"3992_CR136","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.micromeso.2011.07.023","volume":"150","author":"F Chen","year":"2012","unstructured":"Chen F, Zhu Y. Chitosan enclosed mesoporous silica nanoparticles as drug nano-carriers: sensitive response to the narrow pH range. Microporous Mesoporous Mater. 2012;150:83\u20139.","journal-title":"Microporous Mesoporous Mater"},{"key":"3992_CR137","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biomaterials.2017.07.030","volume":"143","author":"R Zhao","year":"2017","unstructured":"Zhao R, Li T, Zheng G, Jiang K, Fan L, Shao J. Simultaneous inhibition of growth and metastasis of hepatocellular carcinoma by co-delivery of ursolic acid and sorafenib using lactobionic acid modified and pH-sensitive chitosan-conjugated mesoporous silica nanocomplex. Biomaterials. 2017;143:1\u201316.","journal-title":"Biomaterials"},{"key":"3992_CR138","doi-asserted-by":"publisher","DOI":"10.1016\/j.cclet.2023.108803","volume":"35","author":"L Sun","year":"2024","unstructured":"Sun L, Luo X, Zhou C, Zhou Z, Sun M. Natural polysaccharide-based smart CXCR4-targeted nano-system for magnified liver fibrosis therapy. Chin Chem Lett. 2024;35:108803.","journal-title":"Chin Chem Lett"},{"key":"3992_CR139","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.ijbiomac.2022.05.095","volume":"211","author":"J Jiao","year":"2022","unstructured":"Jiao J, Yu J, Ji H, Liu A. Synthesis of macromolecular Astragalus polysaccharide-nano selenium complex and the inhibitory effects on HepG2 cells. Int J Biol Macromol. 2022;211:481\u20139.","journal-title":"Int J Biol Macromol"},{"key":"3992_CR140","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.carbpol.2017.12.065","volume":"184","author":"J Wang","year":"2018","unstructured":"Wang J, Bao A, Meng X, Guo H, Zhang Y, Zhao Y, et al. An efficient approach to prepare sulfated polysaccharide and evaluation of anti-tumor activities in vitro. Carbohydr Polym. 2018;184:366\u201375.","journal-title":"Carbohydr Polym"},{"key":"3992_CR141","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2021.118950","volume":"278","author":"H Wang","year":"2022","unstructured":"Wang H, Li Y, Wang X, Li Y, Cui J, Jin D-Q, et al. Preparation and structural properties of selenium modified heteropolysaccharide from the fruits of Akebia quinata and in vitro and in vivo antitumor activity. Carbohydr Polym. 2022;278:118950.","journal-title":"Carbohydr Polym"},{"key":"3992_CR142","doi-asserted-by":"publisher","DOI":"10.1002\/admi.202100809","volume":"8","author":"A Dodero","year":"2021","unstructured":"Dodero A, Alberti S, Gaggero G, Ferretti M, Botter R, Vicini S, et al. An up\u2010to\u2010date review on alginate nanoparticles and nanofibers for biomedical and pharmaceutical applications. Adv Mater Interfaces. 2021;8:2100809.","journal-title":"Adv Mater Interfaces"},{"key":"3992_CR143","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2019.104978","volume":"137","author":"L Tunki","year":"2019","unstructured":"Tunki L, Kulhari H, Vadithe LN, Kuncha M, Bhargava S, Pooja D, et al. Modulating the site-specific oral delivery of sorafenib using sugar-grafted nanoparticles for hepatocellular carcinoma treatment. Eur J Pharm Sci. 2019;137:104978.","journal-title":"Eur J Pharm Sci"},{"key":"3992_CR144","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1586\/erm.09.15","volume":"9","author":"J-M L\u00fc","year":"2009","unstructured":"L\u00fc J-M, Xinwen W, Christian M-M, Hao W, H. LP, Qizhi Y, et al. Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn. 2009;9:325\u201341.","journal-title":"Expert Rev Mol Diagn"},{"key":"3992_CR145","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.2217\/nnm-2018-0046","volume":"13","author":"Y Su","year":"2018","unstructured":"Su Y, Wang K, Li Y, Song W, Xin Y, Zhao W, et al. Sorafenib-loaded polymeric micelles as passive targeting therapeutic agents for hepatocellular carcinoma therapy. Nanomedicine. 2018;13:1009\u201323.","journal-title":"Nanomedicine"},{"key":"3992_CR146","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","volume":"161","author":"F Danhier","year":"2012","unstructured":"Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Pr\u00e9at V. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012;161:505\u201322.","journal-title":"J Control Release"},{"key":"3992_CR147","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.3390\/polym16182606","volume":"16","author":"J Yang","year":"2024","unstructured":"Yang J, Zeng H, Luo Y, Chen Y, Wang M, Wu C, et al. Recent applications of PLGA in drug delivery systems. Polymers. 2024;16:2606.","journal-title":"Polymers"},{"key":"3992_CR148","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-023-02502-1","volume":"24","author":"R Mahar","year":"2023","unstructured":"Mahar R, Chakraborty A, Nainwal N, Bahuguna R, Sajwan M, Jakhmola V. Application of PLGA as a biodegradable and biocompatible polymer for pulmonary delivery of drugs. AAPS PharmSciTech. 2023;24:39.","journal-title":"AAPS PharmSciTech"},{"key":"3992_CR149","first-page":"5087","volume":"3","author":"A Verma","year":"2012","unstructured":"Verma A, Ratnawat S, Gupta AK, Jain S. PLGA: a polymer of choice as nanocarrier\u2019s to achieve effective delivery of medicinal substances. Int J Pharm Sci Res. 2012;3:5087.","journal-title":"Int J Pharm Sci Res"},{"key":"3992_CR150","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/0168-3659(94)00084-8","volume":"33","author":"TG Park","year":"1995","unstructured":"Park TG, Lu W, Crotts G. Importance of in vitro experimental conditions on protein release kinetics, stability and polymer degradation in protein encapsulated poly (D, L-lactic acid-co-glycolic acid) microspheres. J Control Release. 1995;33:211\u201322.","journal-title":"J Control Release"},{"key":"3992_CR151","doi-asserted-by":"publisher","DOI":"10.3390\/polym10080895","volume":"10","author":"G Babos","year":"2018","unstructured":"Babos G, Bir\u00f3 E, Meiczinger M, Feczk\u00f3 T. Dual drug delivery of Sorafenib and Doxorubicin from PLGA and PEG-PLGA polymeric nanoparticles. Polymers. 2018;10:895.","journal-title":"Polymers"},{"key":"3992_CR152","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1465363","volume":"15","author":"A Mateen","year":"2024","unstructured":"Mateen A, Khan A, Khan I, Ahmad L, Khan A, Salam A. Formulation development, characterization, and evaluation of sorafenib-loaded PLGA\u2013chitosan nanoparticles. Front Pharmacol. 2024;15:1465363.","journal-title":"Front Pharmacol"},{"key":"3992_CR153","doi-asserted-by":"publisher","DOI":"10.34133\/research.0477","volume":"7","author":"Z Tang","year":"2024","unstructured":"Tang Z, Deng L, Zhang J, Jiang T, Xiang H, Chen Y, et al. Intelligent hydrogel-assisted hepatocellular carcinoma therapy. Research. 2024;7:0477.","journal-title":"Research"},{"key":"3992_CR154","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1016\/j.drudis.2021.04.012","volume":"26","author":"AC Marques","year":"2021","unstructured":"Marques AC, Costa PJ, Velho S, Amaral MH. Stimuli-responsive hydrogels for intratumoral drug delivery. Drug Discov Today. 2021;26:2397\u2013405.","journal-title":"Drug Discov Today"},{"key":"3992_CR155","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2019.05.031","volume":"216","author":"L Zheng","year":"2019","unstructured":"Zheng L, Li Ce, Huang X, Lin X, Lin W, Yang F, et al. Thermosensitive hydrogels for sustained-release of sorafenib and selenium nanoparticles for localized synergistic chemoradiotherapy. Biomaterials. 2019;216:119220.","journal-title":"Biomaterials"},{"key":"3992_CR156","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202300733","volume":"20","author":"J Gong","year":"2024","unstructured":"Gong J, Hu J, Yan X, Xiang L, Chen S, Yang H, et al. Injectable hydrogels including magnetic nanosheets for multidisciplinary treatment of hepatocellular carcinoma via magnetic hyperthermia. Small. 2024;20:2300733.","journal-title":"Small"},{"key":"3992_CR157","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1039\/C9TB01891C","volume":"8","author":"H Yang","year":"2020","unstructured":"Yang H, Liu H-s, Hou W, Gao J-x, Duan Y, Wei D, et al. An NIR-responsive mesoporous silica nanosystem for synergetic photothermal-immunoenhancement therapy of hepatocellular carcinoma. J Mater Chem B. 2020;8:251\u20139.","journal-title":"J Mater Chem B"},{"key":"3992_CR158","doi-asserted-by":"publisher","DOI":"10.1002\/btm2.10558","volume":"8","author":"MX Liu","year":"2023","unstructured":"Liu MX, Xu L, Jiang JY, Dong HC, Zhu PF, Cao L, et al. Light controlled self-escape capability of non-cationic carbon nitride-based nanosheets in lysosomes for hepatocellular carcinoma targeting stimulus-responsive gene delivery. Bioeng Transl Med. 2023;8:e10558.","journal-title":"Bioeng Transl Med"},{"key":"3992_CR159","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S223920","author":"MM Elsayed","year":"2019","unstructured":"Elsayed MM, Mostafa ME, Alaaeldin E, Sarhan HA, Shaykoon MS, Allam S, et al. Design and characterisation of novel Sorafenib-loaded carbon nanotubes with distinct tumour-suppressive activity in hepatocellular carcinoma. Int J Nanomedicine. 2019. https:\/\/doi.org\/10.2147\/IJN.S223920.","journal-title":"Int J Nanomedicine"},{"key":"3992_CR160","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1080\/03639045.2019.1629688","volume":"45","author":"J Wang","year":"2019","unstructured":"Wang J, Yamin Z, Lei L, Zilin C, Xiaolong L, Lianjiang W, et al. Combined chemo\/photothermal therapy based on mesoporous silica-Au core-shell nanoparticles for hepatocellular carcinoma treatment. Drug Dev Ind Pharm. 2019;45:1487\u201395.","journal-title":"Drug Dev Ind Pharm"},{"key":"3992_CR161","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.bcp.2018.12.003","volume":"160","author":"JK Tee","year":"2019","unstructured":"Tee JK, Peng F, Ho HK. Effects of inorganic nanoparticles on liver fibrosis: optimizing a double-edged sword for therapeutics. Biochem Pharmacol. 2019;160:24\u201333.","journal-title":"Biochem Pharmacol"},{"key":"3992_CR162","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1002\/anie.200602866","volume":"46","author":"AH Lu","year":"2007","unstructured":"Lu AH, Salabas EeL, Sch\u00fcth F. Magnetic nanoparticles: synthesis, protection, functionalization, and application. Angew Chem Int Ed. 2007;46:1222\u201344.","journal-title":"Angew Chem Int Ed"},{"key":"3992_CR163","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1049\/iet-nbt.2020.0139","volume":"14","author":"\u015e Alpdemir","year":"2020","unstructured":"Alpdemir \u015e, Vural T, Kara G, Bayram C, Haberal E, Denkba\u015f EB. Magnetically responsive, sorafenib loaded alginate microspheres for hepatocellular carcinoma treatment. IET Nanobiotechnol. 2020;14:617\u201322.","journal-title":"IET Nanobiotechnol"},{"key":"3992_CR164","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1007\/s12274-017-1444-3","volume":"10","author":"N Depalo","year":"2017","unstructured":"Depalo N, Iacobazzi RM, Valente G, Arduino I, Villa S, Canepa F, et al. Sorafenib delivery nanoplatform based on superparamagnetic iron oxide nanoparticles magnetically targets hepatocellular carcinoma. Nano Res. 2017;10:2431\u201348.","journal-title":"Nano Res"},{"key":"3992_CR165","volume":"19","author":"H Barabadi","year":"2020","unstructured":"Barabadi H, Webster TJ, Vahidi H, Sabori H, Kamali KD, Shoushtari FJ, et al. Green nanotechnology-based gold nanomaterials for hepatic cancer therapeutics: a systematic review. Iran j pharm Res: IJPR. 2020;19:3.","journal-title":"Iran j pharm Res: IJPR"},{"key":"3992_CR166","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.7150\/ijms.37427","volume":"16","author":"H Cai","year":"2019","unstructured":"Cai H, Yang Y, Peng F, Liu Y, Fu X, Ji B. Gold nanoparticles-loaded anti-miR221 enhances antitumor effect of sorafenib in hepatocellular carcinoma cells. Int J Med Sci. 2019;16:1541.","journal-title":"Int J Med Sci"},{"key":"3992_CR167","doi-asserted-by":"publisher","first-page":"3296","DOI":"10.1557\/jmr.2020.321","volume":"35","author":"J Chen","year":"2020","unstructured":"Chen J, Huang J. Sorafenib delivered by cancer cell membrane remodels tumor microenvironment to enhances the immunotherapy of mitoxantrone in breast cancer. J Mater Res. 2020;35:3296\u2013303.","journal-title":"J Mater Res"},{"key":"3992_CR168","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-021-01095-w","volume":"19","author":"Z Li","year":"2021","unstructured":"Li Z, Yang G, Han L, Wang R, Gong C, Yuan Y. Sorafenib and triptolide loaded cancer cell-platelet hybrid membrane-camouflaged liquid crystalline lipid nanoparticles for the treatment of hepatocellular carcinoma. J Nanobiotechnology. 2021;19:360.","journal-title":"J Nanobiotechnology"},{"issue":"1","key":"3992_CR169","doi-asserted-by":"publisher","DOI":"10.1080\/20013078.2019.1648167","volume":"8","author":"KW Witwer","year":"2019","unstructured":"Witwer KW, Th\u00e9ry C. Extracellular vesicles or exosomes? On primacy, precision, and popularity influencing a choice of nomenclature. J Extracell Vesicles. 2019;8(1):1648167.","journal-title":"J Extracell Vesicles"},{"key":"3992_CR170","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25031629","volume":"25","author":"FM Filannino","year":"2024","unstructured":"Filannino FM, Panaro MA, Benameur T, Pizzolorusso I, Porro C. Extracellular vesicles in the central nervous system: a novel mechanism of neuronal cell communication. Int J Mol Sci. 2024;25:1629.","journal-title":"Int J Mol Sci"},{"key":"3992_CR171","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2020.120467","volume":"269","author":"P Wu","year":"2021","unstructured":"Wu P, Zhang B, Ocansey DKW, Xu W, Qian H. Extracellular vesicles: a bright star of nanomedicine. Biomaterials. 2021;269:120467.","journal-title":"Biomaterials"},{"key":"3992_CR172","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.jconrel.2020.08.018","volume":"327","author":"L Cabeza","year":"2020","unstructured":"Cabeza L, Perazzoli G, Pe\u00f1a M, Cepero A, Luque C, Melguizo C, et al. Cancer therapy based on extracellular vesicles as drug delivery vehicles. J Control Release. 2020;327:296\u2013315.","journal-title":"J Control Release"},{"key":"3992_CR173","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/s41565-021-00931-2","volume":"16","author":"IK Herrmann","year":"2021","unstructured":"Herrmann IK, Wood MJA, Fuhrmann G. Extracellular vesicles as a next-generation drug delivery platform. Nat Nanotechnol. 2021;16:748\u201359.","journal-title":"Nat Nanotechnol"},{"key":"3992_CR174","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2023.106604","volume":"191","author":"Z Fang","year":"2023","unstructured":"Fang Z, Song M, Lai K, Cui M, Yin M, Liu K. Kiwi-derived extracellular vesicles for oral delivery of sorafenib. Eur J Pharm Sci. 2023;191:106604.","journal-title":"Eur J Pharm Sci"},{"key":"3992_CR175","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12030","volume":"10","author":"G Zhang","year":"2020","unstructured":"Zhang G, Huang X, Xiu H, Sun Y, Chen J, Cheng G, et al. Extracellular vesicles: natural liver\u2010accumulating drug delivery vehicles for the treatment of liver diseases. J Extracell Vesicles. 2020;10:e12030.","journal-title":"J Extracell Vesicles"},{"key":"3992_CR176","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12951-023-01902-6","volume":"21","author":"C He","year":"2023","unstructured":"He C, Jaffar Ali D, Qi Y, Li Y, Sun B, Liu R, et al. Engineered extracellular vesicles mediated CRISPR-induced deficiency of IQGAP1\/FOXM1 reverses sorafenib resistance in HCC by suppressing cancer stem cells. J Nanobiotechnology. 2023;21:154.","journal-title":"J Nanobiotechnology"},{"key":"3992_CR177","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2025.101943","author":"Y Xu","year":"2025","unstructured":"Xu Y, Cai X, Wu J, Zheng Y, Wang Y. Colonization of engineered bacteria enhanced lipid nanomedicine accumulation in tumors for sonodynamic immunotherapy. Mater Today Bio. 2025. https:\/\/doi.org\/10.1016\/j.mtbio.2025.101943.","journal-title":"Mater Today Bio"},{"key":"3992_CR178","doi-asserted-by":"publisher","first-page":"1903793","DOI":"10.1002\/adma.201903793","volume":"31","author":"Q Song","year":"2019","unstructured":"Song Q, Zheng C, Jia J, Zhao H, Feng Q, Zhang H, et al. A probiotic spore-based oral autonomous nanoparticles generator for cancer therapy. Adv Mater. 2019;31:1903793.","journal-title":"Adv Mater"},{"key":"3992_CR179","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2024.1437301","volume":"12","author":"A Armstrong","year":"2024","unstructured":"Armstrong A, Isalan M. Engineering bacterial theranostics: from logic gates to in vivo applications. Front Bioeng Biotechnol. 2024;12:1437301.","journal-title":"Front Bioeng Biotechnol"},{"key":"3992_CR180","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15102490","volume":"15","author":"R Zong","year":"2023","unstructured":"Zong R, Ruan H, Liu C, Fan S, Li J. Bacteria and bacterial components as natural bio-nanocarriers for drug and gene delivery systems in cancer therapy. Pharmaceutics. 2023;15:2490.","journal-title":"Pharmaceutics"},{"key":"3992_CR181","doi-asserted-by":"publisher","first-page":"758","DOI":"10.22270\/jddt.v9i3-s.2750","volume":"9","author":"P Deepak","year":"2019","unstructured":"Deepak P, Seema P, Sarvesh P, Gargi P, Swapnil S. Nanostructured lipid carriers: a platform to lipophilic drug for oral bioavailability enhancement. J Drug Deliv Ther. 2019;9:758\u201364.","journal-title":"J Drug Deliv Ther"},{"key":"3992_CR182","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2019.101185","volume":"53","author":"V-A Duong","year":"2019","unstructured":"Duong V-A, Maeng H-J, Chi S-C. Nanostructured lipid carriers containing ondansetron hydrochloride by cold high-pressure homogenization method: preparation, characterization, and pharmacokinetic evaluation. J Drug Deliv Sci Technol. 2019;53:101185.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3992_CR183","doi-asserted-by":"publisher","first-page":"6939","DOI":"10.1039\/D4NR00278D","volume":"16","author":"B Misra","year":"2024","unstructured":"Misra B, Hughes KA, Pentz WH, Samart P, Geldenhuys WJ, Bobbala S. Flash nanoprecipitation assisted self-assembly of ionizable lipid nanoparticles for nucleic acid delivery. Nanoscale. 2024;16:6939\u201348.","journal-title":"Nanoscale"},{"key":"3992_CR184","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2023.115044","volume":"200","author":"C Guo","year":"2023","unstructured":"Guo C, Yuan H, Wang Y, Feng Y, Zhang Y, Yin T, et al. The interplay between PEGylated nanoparticles and blood immune system. Adv Drug Deliv Rev. 2023;200:115044.","journal-title":"Adv Drug Deliv Rev"},{"key":"3992_CR185","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11051-012-1316-4","volume":"14","author":"E Locatelli","year":"2012","unstructured":"Locatelli E, Comes Franchini M. Biodegradable PLGA-b-PEG polymeric nanoparticles: synthesis, properties, and nanomedical applications as drug delivery system. J Nanopart Res. 2012;14:1\u201317.","journal-title":"J Nanopart Res"},{"key":"3992_CR186","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/jbm.a.32654","volume":"94","author":"SA Burns","year":"2010","unstructured":"Burns SA, Hard R, Hicks Jr Jr., Bright FV, Cohan D, Sigurdson L, et al. Determining the protein drug release characteristics and cell adhesion to a PLLA or PLGA biodegradable polymer membrane. J Biomed Mater Res Part A: An Official J Soc Biomater Jpn Soc Biomater Aust Soc Biomater Korean Soc Biomater. 2010;94:27\u201337.","journal-title":"J Biomed Mater Res Part A: An Official J Soc Biomater Jpn Soc Biomater Aust Soc Biomater Korean Soc Biomater"},{"key":"3992_CR187","first-page":"2409422","volume-title":"Biodegradable polymers for application as robust immunomodulatory biomaterial carrier systems","author":"BG Barbery","year":"2025","unstructured":"Barbery BG, Lukesh NR, Bachelder EM, Ainslie KM. Biodegradable polymers for application as robust immunomodulatory biomaterial carrier systems. 2025. p. 2409422."},{"key":"3992_CR188","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.4c20890","author":"Y Tian","year":"2025","unstructured":"Tian Y, Lv H, Ju Y, Hao J, Cui J. Zwitterionic poly (ethylene glycol) nanoparticles minimize protein adsorption and immunogenicity for improved biological fate. ACS Appl Mater Interfaces. 2025. https:\/\/doi.org\/10.1021\/acsami.4c20890.","journal-title":"ACS Appl Mater Interfaces"},{"key":"3992_CR189","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.biomaterials.2018.07.060","volume":"181","author":"L Zhang","year":"2018","unstructured":"Zhang L, Zhang M, Zhou L, Han Q, Chen X, Li S, et al. Dual drug delivery and sequential release by amphiphilic Janus nanoparticles for liver cancer theranostics. Biomaterials. 2018;181:113\u201325.","journal-title":"Biomaterials"},{"key":"3992_CR190","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2025.114501","volume":"249","author":"F Espinola-Portilla","year":"2025","unstructured":"Espinola-Portilla F, d\u2019Orly\u00e9 F, Gonz\u00e1lez JAM, Trapiella-Alfonso L, Guti\u00e9rrez-Granados S, Varenne A, et al. Upconverting\/magnetic Janus-like nanoparticles integrated into spiropyran micelle-like nanocarriers for NIR light-and pH-responsive drug delivery, photothermal therapy and biomedical imaging. Colloids Surf B Biointerfaces. 2025;249:114501.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"3992_CR191","doi-asserted-by":"publisher","first-page":"7885","DOI":"10.1039\/C4NR07335E","volume":"7","author":"H Wang","year":"2015","unstructured":"Wang H, Cao G, Gai Z, Hong K, Banerjee P, Zhou S. Magnetic\/NIR-responsive drug carrier, multicolor cell imaging, and enhanced photothermal therapy of gold capped magnetite-fluorescent carbon hybrid nanoparticles. Nanoscale. 2015;7:7885\u201395.","journal-title":"Nanoscale"},{"key":"3992_CR192","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21176305","volume":"21","author":"C Liao","year":"2020","unstructured":"Liao C, Jin Y, Li Y, Tjong SC. Interactions of zinc oxide nanostructures with mammalian cells: cytotoxicity and photocatalytic toxicity. Int J Mol Sci. 2020;21:6305.","journal-title":"Int J Mol Sci"},{"key":"3992_CR193","doi-asserted-by":"publisher","first-page":"8780","DOI":"10.1021\/nn403202w","volume":"7","author":"L Guo","year":"2013","unstructured":"Guo L, Panderi I, Yan DD, Szulak K, Li Y, Chen Y-T, et al. A comparative study of hollow copper sulfide nanoparticles and hollow gold nanospheres on degradability and toxicity. ACS Nano. 2013;7:8780\u201393.","journal-title":"ACS Nano"},{"key":"3992_CR194","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtchem.2020.100381","volume":"18","author":"A Shetty","year":"2020","unstructured":"Shetty A, Chandra S. Inorganic hybrid nanoparticles in cancer theranostics: understanding their combinations for better clinical translation. Mater Today Chem. 2020;18:100381.","journal-title":"Mater Today Chem"},{"key":"3992_CR195","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioadv.2023.213456","volume":"151","author":"S Rezaei","year":"2023","unstructured":"Rezaei S, de Ara\u00fajo J\u00fanior RF, da Silva ILG, Schomann T, Eich C, Cruz LJ. Erythrocyte\u2212 cancer hybrid membrane-coated reduction-sensitive nanoparticles for enhancing chemotherapy efficacy in breast cancer. Biomater Adv. 2023;151:213456.","journal-title":"Biomater Adv"},{"key":"3992_CR196","doi-asserted-by":"publisher","first-page":"7836","DOI":"10.1021\/acs.nanolett.9b02841","volume":"19","author":"C Liu","year":"2019","unstructured":"Liu C, Zhang W, Li Y, Chang J, Tian F, Zhao F, et al. Microfluidic sonication to assemble exosome membrane-coated nanoparticles for immune evasion-mediated targeting. Nano Lett. 2019;19:7836\u201344.","journal-title":"Nano Lett"},{"key":"3992_CR197","doi-asserted-by":"publisher","DOI":"10.3390\/biom13020278","volume":"13","author":"M Soares","year":"2023","unstructured":"Soares M, Pinto MM, Nobre RJ, de Almeida LP, da Gra\u00e7a Rasteiro M, Almeida-Santos T, et al. Isolation of extracellular vesicles from human follicular fluid: size-exclusion chromatography versus ultracentrifugation. Biomolecules. 2023;13:278.","journal-title":"Biomolecules"},{"key":"3992_CR198","doi-asserted-by":"publisher","DOI":"10.1038\/srep33641","volume":"6","author":"A G\u00e1mez-Valero","year":"2016","unstructured":"G\u00e1mez-Valero A, Mongui\u00f3-Tortajada M, Carreras-Planella L, Franquesa Ml, Beyer K, Borr\u00e0s FE. Size-exclusion chromatography-based isolation minimally alters extracellular vesicles\u2019 characteristics compared to precipitating agents. Sci Rep. 2016;6:33641.","journal-title":"Sci Rep"},{"key":"3992_CR199","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.omtm.2019.01.001","volume":"13","author":"MAC Pomatto","year":"2019","unstructured":"Pomatto MAC, Bussolati B, D\u2019Antico S, Ghiotto S, Tetta C, Brizzi MF, et al. Improved loading of plasma-derived extracellular vesicles to encapsulate antitumor miRNAs. Mol Ther Methods Clin Dev. 2019;13:133\u201344.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"3992_CR200","doi-asserted-by":"publisher","first-page":"1159193","DOI":"10.3389\/fbioe.2023.1159193","volume":"11","author":"D Kulkarni","year":"2023","unstructured":"Kulkarni D, Sherkar R, Shirsathe C, Sonwane R, Varpe N, Shelke S, et al. Biofabrication of nanoparticles: sources, synthesis, and biomedical applications. Front Bioeng Biotechnol. 2023;11:1159193.","journal-title":"Front Bioeng Biotechnol"},{"key":"3992_CR201","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1634\/theoncologist.2007-0233","volume":"13","author":"L Dal Lago","year":"2008","unstructured":"Dal Lago L, D\u2019Hondt V, Awada A. Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors. Oncologist. 2008;13:845\u201358.","journal-title":"Oncologist"},{"key":"3992_CR202","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/j.nano.2016.01.017","volume":"12","author":"J Zhang","year":"2016","unstructured":"Zhang J, Hu J, Chan HF, Skibba M, Liang G, Chen M. iRGD decorated lipid-polymer hybrid nanoparticles for targeted co-delivery of doxorubicin and sorafenib to enhance anti-hepatocellular carcinoma efficacy. Nanomedicine Nanotechnol Biol Med. 2016;12:1303\u201311.","journal-title":"Nanomedicine Nanotechnol Biol Med"},{"key":"3992_CR203","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1166\/jbn.2020.2975","volume":"16","author":"Y Peng","year":"2020","unstructured":"Peng Y, Su Z, Wang X, Wu T, Xiao H, Shuai X, et al. Near-infrared light laser-triggered release of doxorubicin and sorafenib from temperaturesensitive liposomes for synergistic therapy of hepatocellular carcinoma. J Biomed Nanotechnol. 2020;16:1381\u201393.","journal-title":"J Biomed Nanotechnol"},{"key":"3992_CR204","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0083627","volume":"8","author":"W-C Huang","year":"2013","unstructured":"Huang W-C, Hsieh Y-L, Hung C-M, Chien P-H, Chien Y-F, Chen L-C, et al. BCRP\/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenib. PLoS One. 2013;8:e83627.","journal-title":"PLoS One"},{"key":"3992_CR205","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1158\/1538-7445.AM2022-2621","volume":"82","author":"Y Qian","year":"2022","unstructured":"Qian Y, Basu R, Mathes S, Kulkarni P, Davis E, Berryman D, et al. Growth hormone receptor antagonist sensitizes melanoma and hepatocarcinoma to drug treatments via downregulation of ABC transporters in vivo. Cancer Res. 2022;82:2621\u20132621.","journal-title":"Cancer Res"},{"key":"3992_CR206","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.ejps.2017.10.036","volume":"111","author":"G Zheng","year":"2018","unstructured":"Zheng G, Zhao R, Xu A, Shen Z, Chen X, Shao J. Co-delivery of sorafenib and siVEGF based on mesoporous silica nanoparticles for ASGPR mediated targeted HCC therapy. Eur J Pharm Sci. 2018;111:492\u2013502.","journal-title":"Eur J Pharm Sci"},{"key":"3992_CR207","doi-asserted-by":"publisher","first-page":"2003042","DOI":"10.1002\/advs.202003042","volume":"8","author":"S Xu","year":"2021","unstructured":"Xu S, Ling S, Shan Q, Ye Q, Zhan Q, Jiang G, et al. Self-activated cascade-responsive sorafenib and USP22 shRNA co-delivery system for synergetic hepatocellular carcinoma therapy. Adv Sci. 2021;8:2003042.","journal-title":"Adv Sci"},{"key":"3992_CR208","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.jcis.2021.09.174","volume":"608","author":"RM Iacobazzi","year":"2022","unstructured":"Iacobazzi RM, Vischio F, Arduino I, Canepa F, Laquintana V, Notarnicola M, et al. Magnetic implants in vivo guiding sorafenib liver delivery by superparamagnetic solid lipid nanoparticles. J Colloid Interface Sci. 2022;608:239\u201354.","journal-title":"J Colloid Interface Sci"},{"key":"3992_CR209","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.121184","volume":"279","author":"DM Francis","year":"2021","unstructured":"Francis DM, Manspeaker MP, Archer PA, Sestito LF, Heiler AJ, Schudel A, et al. Drug-eluting immune checkpoint blockade antibody-nanoparticle conjugate enhances locoregional and systemic combination cancer immunotherapy through T lymphocyte targeting. Biomaterials. 2021;279:121184.","journal-title":"Biomaterials"},{"key":"3992_CR210","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1159\/000512170","volume":"9","author":"M Kudo","year":"2020","unstructured":"Kudo M. Limited impact of anti-PD-1\/PD-L1 monotherapy for hepatocellular carcinoma. Liver Cancer. 2020;9:629\u201339.","journal-title":"Liver Cancer"},{"key":"3992_CR211","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.216038","volume":"555","author":"Z Wang","year":"2023","unstructured":"Wang Z, Wang Y, Gao P, Ding J. Immune checkpoint inhibitor resistance in hepatocellular carcinoma. Cancer Lett. 2023;555:216038.","journal-title":"Cancer Lett"},{"key":"3992_CR212","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12006-1","volume":"24","author":"X Da","year":"2024","unstructured":"Da X, Cao B, Mo J, Xiang Y, Hu H, Qiu C, et al. Inhibition of growth of hepatocellular carcinoma by co-delivery of anti-PD-1 antibody and sorafenib using biomimetic nano-platelets. BMC Cancer. 2024;24:273.","journal-title":"BMC Cancer"},{"key":"3992_CR213","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.130162","volume":"263","author":"Y Chen","year":"2024","unstructured":"Chen Y, Jiang Z, Yan Z, Liu J, Lai Y, Li L, et al. A codelivery system loaded with PDL1-siRNA and sorafenib enhances the therapeutic effect of sorafenib on hepatocellular carcinoma via TAT-poly-SS-lysine modified chitosan. Int J Biol Macromol. 2024;263:130162.","journal-title":"Int J Biol Macromol"},{"key":"3992_CR214","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114798","volume":"163","author":"S Wei","year":"2023","unstructured":"Wei S, Wei F, Li M, Yang Y, Zhang J, Li C, et al. Target immune components to circumvent sorafenib resistance in hepatocellular carcinoma. Biomed Pharmacother. 2023;163:114798.","journal-title":"Biomed Pharmacother"},{"key":"3992_CR215","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000481246","volume":"93","author":"N Nishida","year":"2017","unstructured":"Nishida N, Kudo M. Oncogenic signal and tumor microenvironment in hepatocellular carcinoma. Oncology. 2017;93:160\u20134.","journal-title":"Oncology"},{"key":"3992_CR216","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jconrel.2024.06.030","volume":"372","author":"J Ke","year":"2024","unstructured":"Ke J, Liu Y, Liu F, Cai H, Li X, Zhang Z, et al. In-situ-formed immunotherapeutic and hemostatic dual drug-loaded nanohydrogel for preventing postoperative recurrence of hepatocellular carcinoma. J Control Release. 2024;372:141\u201354.","journal-title":"J Control Release"},{"key":"3992_CR217","first-page":"147","volume":"17","author":"Y Wang","year":"2022","unstructured":"Wang Y, Wang Z, Jia F, Xu Q, Shu Z, Deng J, et al. CXCR4-guided liposomes regulating hypoxic and immunosuppressive microenvironment for sorafenib-resistant tumor treatment. Bioact Mater. 2022;17:147\u201361.","journal-title":"Bioact Mater"},{"key":"3992_CR218","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.biomaterials.2015.07.035","volume":"67","author":"D-Y Gao","year":"2015","unstructured":"Gao D-Y, Lin T-T, Sung Y-C, Liu YC, Chiang W-H, Chang C-C, et al. CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer. Biomaterials. 2015;67:194\u2013203.","journal-title":"Biomaterials"},{"key":"3992_CR219","first-page":"24010003","volume-title":"Ai-driven design and optimization of nanoparticle-based drug delivery systems","author":"DU Kapoor","year":"2024","unstructured":"Kapoor DU, Sharma JB, Gandhi SM, Prajapati BG, Thanawuth K, Limmatvapirat S, et al. Ai-driven design and optimization of nanoparticle-based drug delivery systems. Engineering and Health Studies: Science; 2024. p. 24010003\u201324010003."},{"key":"3992_CR220","doi-asserted-by":"publisher","DOI":"10.1063\/5.0057204","author":"I Tom\u00e9","year":"2021","unstructured":"Tom\u00e9 I, Francisco V, Fernandes H, Ferreira L. High-throughput screening of nanoparticles in drug delivery. APL Bioeng. 2021. https:\/\/doi.org\/10.1063\/5.0057204.","journal-title":"APL Bioeng"},{"key":"3992_CR221","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12943-025-02321-x","volume":"24","author":"Y Mao","year":"2025","unstructured":"Mao Y, Shangguan D, Huang Q, Xiao L, Cao D, Zhou H, et al. Emerging artificial intelligence-driven precision therapies in tumor drug resistance: recent advances, opportunities, and challenges. Mol Cancer. 2025;24:123.","journal-title":"Mol Cancer"},{"key":"3992_CR222","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jconrel.2023.06.040","volume":"360","author":"DM Azagury","year":"2023","unstructured":"Azagury DM, Gluck BF, Harris Y, Avrutin Y, Niezni D, Sason H, et al. Prediction of cancer nanomedicines self-assembled from meta-synergistic drug pairs. J Control Release. 2023;360:418\u201332.","journal-title":"J Control Release"},{"key":"3992_CR223","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jconrel.2024.08.015","volume":"374","author":"K Mi","year":"2024","unstructured":"Mi K, Chou W-C, Chen Q, Yuan L, Kamineni VN, Kuchimanchi Y, et al. Predicting tissue distribution and tumor delivery of nanoparticles in mice using machine learning models. J Control Release. 2024;374:219\u201329.","journal-title":"J Control Release"},{"key":"3992_CR224","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1038\/s41589-024-01679-1","volume":"20","author":"DB Catacutan","year":"2024","unstructured":"Catacutan DB, Alexander J, Arnold A, Stokes JM. Machine learning in preclinical drug discovery. Nat Chem Biol. 2024;20:960\u201373.","journal-title":"Nat Chem Biol"},{"key":"3992_CR225","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/s41575-019-0240-9","volume":"17","author":"B Chen","year":"2020","unstructured":"Chen B, Garmire L, Calvisi DF, Chua M-S, Kelley RK, Chen X. Harnessing big \u2018omics\u2019 data and AI for drug discovery in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2020;17:238\u201351.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3992_CR226","doi-asserted-by":"publisher","DOI":"10.1016\/j.msec.2021.112100","volume":"125","author":"D Dhamecha","year":"2021","unstructured":"Dhamecha D, Le D, Chakravarty T, Perera K, Dutta A, Menon JU. Fabrication of PNIPAm-based thermoresponsive hydrogel microwell arrays for tumor spheroid formation. Mater Sci Eng C Mater Biol Appl. 2021;125:112100.","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"key":"3992_CR227","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41578-023-00552-2","volume":"8","author":"M Mahmoudi","year":"2023","unstructured":"Mahmoudi M, Landry MP, Moore A, Coreas R. The protein corona from nanomedicine to environmental science. Nat Rev Mater. 2023;8:422\u201338.","journal-title":"Nat Rev Mater"},{"key":"3992_CR228","doi-asserted-by":"publisher","DOI":"10.3390\/bioengineering12030312","volume":"12","author":"T Kopac","year":"2025","unstructured":"Kopac T. Leveraging artificial intelligence and machine learning for characterizing protein corona, nanobiological interactions, and advancing drug discovery. Bioengineering. 2025;12:312.","journal-title":"Bioengineering"},{"key":"3992_CR229","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.135123","volume":"279","author":"N Chaurawal","year":"2024","unstructured":"Chaurawal N, Quadir SS, Joshi G, Barkat MA, Alanezi AA, Raza K. Development of fucoidan\/polyethyleneimine based sorafenib-loaded self-assembled nanoparticles with machine learning and DoE-ANN implementation: optimization, characterization, and in-vitro assessment for the anticancer drug delivery. Int J Biol Macromol. 2024;279:135123.","journal-title":"Int J Biol Macromol"},{"key":"3992_CR230","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41565-021-00870-y","volume":"16","author":"D Reker","year":"2021","unstructured":"Reker D, Rybakova Y, Kirtane AR, Cao R, Yang JW, Navamajiti N, et al. Computationally guided high-throughput design of self-assembling drug nanoparticles. Nat Nanotechnol. 2021;16:725\u201333.","journal-title":"Nat Nanotechnol"},{"key":"3992_CR231","doi-asserted-by":"publisher","first-page":"70","DOI":"10.15575\/join.v9i1.1297","volume":"9","author":"T Addissouky","year":"2024","unstructured":"Addissouky T, Ali MM, El Sayed IET, Alubiady MHS. Realizing the promise of artificial intelligence in hepatocellular carcinoma through opportunities and recommendations for responsible translation. J Online Informatika. 2024;9:70\u20139.","journal-title":"J Online Informatika"},{"key":"3992_CR232","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1216585","volume":"14","author":"Q Gong","year":"2023","unstructured":"Gong Q, Chen X, Liu F, Cao Y. Machine learning-based integration develops a neutrophil-derived signature for improving outcomes in hepatocellular carcinoma. Front Immunol. 2023;14:1216585.","journal-title":"Front Immunol"},{"key":"3992_CR233","doi-asserted-by":"publisher","first-page":"e419","DOI":"10.1038\/emm.2017.164","volume":"50","author":"H Hirschfield","year":"2018","unstructured":"Hirschfield H, Bian CB, Higashi T, Nakagawa S, Zeleke TZ, Nair VD, et al. In vitro modeling of hepatocellular carcinoma molecular subtypes for anti-cancer drug assessment. Exp Mol Med. 2018;50:e419\u2013e419.","journal-title":"Exp Mol Med"},{"key":"3992_CR234","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.525461","volume":"10","author":"B-Y Zhong","year":"2020","unstructured":"Zhong B-Y, Yan Z-P, Sun J-H, Zhang L, Hou Z-H, Yang M-J, et al. Prognostic performance of albumin\u2013bilirubin grade with artificial intelligence for hepatocellular carcinoma treated with transarterial chemoembolization combined with sorafenib. Front Oncol. 2020;10:525461.","journal-title":"Front Oncol"},{"key":"3992_CR235","doi-asserted-by":"publisher","first-page":"10690","DOI":"10.1038\/s41598-023-37862-y","volume":"13","author":"W Dong","year":"2023","unstructured":"Dong W, Ji Y, Pi S, Chen Q-F. Noninvasive imaging-based machine learning algorithm to identify progressive disease in advanced hepatocellular carcinoma receiving second-line systemic therapy. Sci Rep. 2023;13:10690.","journal-title":"Sci Rep"},{"key":"3992_CR236","doi-asserted-by":"publisher","DOI":"10.1038\/s41540-021-00199-1","volume":"7","author":"S Golriz Khatami","year":"2021","unstructured":"Golriz Khatami S, Mubeen S, Bharadhwaj VS, Kodamullil AT, Hofmann-Apitius M, Domingo-Fern\u00e1ndez D. Using predictive machine learning models for drug response simulation by calibrating patient-specific pathway signatures. NPJ Syst Biol Appl. 2021;7:40.","journal-title":"NPJ Syst Biol Appl"},{"key":"3992_CR237","doi-asserted-by":"publisher","first-page":"10614","DOI":"10.1021\/acs.nanolett.4c02823","volume":"24","author":"J Lai","year":"2024","unstructured":"Lai J, Luo Z, Liu J, Hu H, Jiang H, Liu P, et al. Charged gold nanoparticles for target identification-alignment and automatic segmentation of CT image-guided adaptive radiotherapy in small hepatocellular carcinoma. Nano Lett. 2024;24:10614\u201323.","journal-title":"Nano Lett"},{"key":"3992_CR238","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-08668-x","author":"G Jia","year":"2025","unstructured":"Jia G, He P, Dai T, Goh D, Wang J, Sun M, et al. Spatial immune scoring system predicts hepatocellular carcinoma recurrence. Nature. 2025. https:\/\/doi.org\/10.1038\/s41586-025-08668-x.","journal-title":"Nature"},{"key":"3992_CR239","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1126\/science.253.5025.1242","volume":"253","author":"AK Joshi","year":"1991","unstructured":"Joshi AK. Natural language processing. Science. 1991;253:1242\u20139.","journal-title":"Science"},{"key":"3992_CR240","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.4_suppl.270","volume-title":"A phase 2 and biomarker study of sorafenib combined with FOLFOX in patients with advanced hepatocellular carcinoma (HCC)","author":"L Goyal","year":"2018","unstructured":"Goyal L, Zheng H, Abrams TA, Miksad RA, Bullock AJ, Allen JN, et al. A phase 2 and biomarker study of sorafenib combined with FOLFOX in patients with advanced hepatocellular carcinoma (HCC). American Society of Clinical Oncology; 2018."},{"key":"3992_CR241","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1158\/1078-0432.CCR-18-0847","volume":"25","author":"L Goyal","year":"2019","unstructured":"Goyal L, Zheng H, Abrams TA, Miksad R, Bullock AJ, Allen JN, et al. A phase II and biomarker study of sorafenib combined with modified FOLFOX in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2019;25:80\u20139.","journal-title":"Clin Cancer Res"},{"key":"3992_CR242","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S543741","author":"L Liang","year":"2025","unstructured":"Liang L, Zhou J, Huang J, Guo Y, Zhou Z, Chen Y, et al. Sorafenib combined with Tislelizumab and transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a phase II study. Immunotargets Ther. 2025. https:\/\/doi.org\/10.2147\/ITT.S543741.","journal-title":"Immunotargets Ther"},{"key":"3992_CR243","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109223","volume":"112","author":"T-R Peng","year":"2022","unstructured":"Peng T-R, Wu CC, Chang S-Y, Chen Y-C, Wu T-W, Hsu C-S. Therapeutic efficacy of nivolumab plus sorafenib therapy in patients with unresectable hepatocellular carcinoma. Int Immunopharmacol. 2022;112:109223.","journal-title":"Int Immunopharmacol"},{"key":"3992_CR244","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1001\/jamaoncol.2019.2792","volume":"5","author":"GK Abou-Alfa","year":"2019","unstructured":"Abou-Alfa GK, Shi Q, Knox JJ, Kaubisch A, Niedzwiecki D, Posey J, et al. Assessment of treatment with sorafenib plus doxorubicin vs sorafenib alone in patients with advanced hepatocellular carcinoma: phase 3 CALGB 80802 randomized clinical trial. JAMA Oncol. 2019;5:1582\u20138.","journal-title":"JAMA Oncol"},{"key":"3992_CR245","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1200\/JCO.2013.53.7746","volume":"33","author":"AX Zhu","year":"2015","unstructured":"Zhu AX, Rosmorduc O, Evans TJ, Ross PJ, Santoro A, Carrilho FJ, et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2015;33:559\u201366.","journal-title":"J Clin Oncol"},{"key":"3992_CR246","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet. 2017;389:2492\u2013502.","journal-title":"Lancet"},{"key":"3992_CR247","doi-asserted-by":"publisher","first-page":"5464","DOI":"10.7150\/thno.54822","volume":"11","author":"FH Kong","year":"2021","unstructured":"Kong FH, Ye QF, Miao XY, Liu X, Huang SQ, Xiong L, et al. Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma. Theranostics. 2021;11:5464\u201390.","journal-title":"Theranostics"},{"key":"3992_CR248","doi-asserted-by":"publisher","DOI":"10.3390\/jfb16040148","volume":"16","author":"P Szyk","year":"2025","unstructured":"Szyk P, Czarczynska-Goslinska B, Ziegler-Borowska M, Larrosa I, Goslinski T. Sorafenib\u2014drug delivery strategies in primary liver cancer. J Funct Biomater. 2025;16:148.","journal-title":"J Funct Biomater"},{"key":"3992_CR249","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3389\/fbioe.2019.00415","volume":"7","author":"OS Thomas","year":"2019","unstructured":"Thomas OS, Weber W. Overcoming physiological barriers to nanoparticle delivery\u2014are we there yet? Front Bioeng Biotechnol. 2019;7:415.","journal-title":"Front Bioeng Biotechnol"},{"key":"3992_CR250","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3390\/life14060672","volume":"14","author":"MS Gatto","year":"2024","unstructured":"Gatto MS, Johnson MP, Najahi-Missaoui W. Targeted liposomal drug delivery: overview of the current applications and challenges. Life. 2024;14:672.","journal-title":"Life"},{"key":"3992_CR251","doi-asserted-by":"publisher","first-page":"14022","DOI":"10.1021\/acsnano.1c05922","volume":"15","author":"B-M Chen","year":"2021","unstructured":"Chen B-M, Cheng T-L, Roffler SR. Polyethylene glycol immunogenicity: theoretical, clinical, and practical aspects of anti-polyethylene glycol antibodies. ACS Nano. 2021;15:14022\u201348.","journal-title":"ACS Nano"},{"key":"3992_CR252","doi-asserted-by":"publisher","first-page":"4176","DOI":"10.3390\/polym14194176","volume":"14","author":"A Lusina","year":"2022","unstructured":"Lusina A, Nazim T, Ceg\u0142owski M. Poly (2-oxazoline) s as stimuli-responsive materials for biomedical applications: recent developments of Polish scientists. Polymers. 2022;14:4176.","journal-title":"Polymers"},{"key":"3992_CR253","doi-asserted-by":"publisher","first-page":"12298","DOI":"10.1021\/acsnano.1c04213","volume":"15","author":"I Muljajew","year":"2021","unstructured":"Muljajew I, Huschke S, Ramoji A, Cseresny\u00e9s Z, Hoeppener S, Nischang I, et al. Stealth effect of short polyoxazolines in graft copolymers: minor changes of backbone end group determine liver cell-type specificity. ACS Nano. 2021;15:12298\u2013313.","journal-title":"ACS Nano"},{"key":"3992_CR254","volume-title":"Surface modification and functionalization of sorafenib-loaded PLGA nanoparticles for targeting hepatocellular and renal cell carcinoma","author":"I Khan","year":"2023","unstructured":"Khan I, Iqbal Z, Khan A, Ahmad L, Khan A, Khan SA, et al. Surface modification and functionalization of sorafenib-loaded PLGA nanoparticles for targeting hepatocellular and renal cell carcinoma. 2023."},{"key":"3992_CR255","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.csbj.2018.10.012","volume":"16","author":"G Settanni","year":"2018","unstructured":"Settanni G, Sch\u00e4fer T, Muhl C, Barz M, Schmid F. Poly-sarcosine and poly (ethylene-glycol) interactions with proteins investigated using molecular dynamics simulations. Comput Struct Biotechnol J. 2018;16:543\u201350.","journal-title":"Comput Struct Biotechnol J"},{"key":"3992_CR256","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.cej.2017.12.116","volume":"340","author":"S Sanchez-Salcedo","year":"2018","unstructured":"Sanchez-Salcedo S, Vallet-Reg\u00ed M, Shahin SA, Glackin CA, Zink JI. Mesoporous core-shell silica nanoparticles with anti-fouling properties for ovarian cancer therapy. Chem Eng J. 2018;340:114\u201324.","journal-title":"Chem Eng J"},{"key":"3992_CR257","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201706759","volume":"30","author":"RH Fang","year":"2018","unstructured":"Fang RH, Kroll AV, Gao W, Zhang L. Cell membrane coating nanotechnology. Adv Mater. 2018;30:1706759.","journal-title":"Adv Mater"},{"key":"3992_CR258","doi-asserted-by":"publisher","first-page":"8255","DOI":"10.1007\/s12274-022-4462-8","volume":"15","author":"S Feng","year":"2022","unstructured":"Feng S, Ni P, Gong Y, Geng B, Li H, Miao C, et al. Synergistic anti-tumor therapy by a homotypic cell membrane-cloaked biomimetic nanocarrier with exceptionally potent activity against hepatic carcinoma. Nano Res. 2022;15:8255\u201369.","journal-title":"Nano Res"},{"key":"3992_CR259","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s12885-024-12006-1","volume":"24","author":"X Da","year":"2024","unstructured":"Da X, Cao B, Mo J, Xiang Y, Hu H, Qiu C, et al. Inhibition of growth of hepatocellular carcinoma by co-delivery of anti-PD-1 antibody and sorafenib using biomimetic nano-platelets. BMC Cancer. 2024;24:273.","journal-title":"BMC Cancer"},{"key":"3992_CR260","doi-asserted-by":"publisher","DOI":"10.2174\/0115672018377065250717004240","volume-title":"Cancer cell-coated PLGA nanoparticles loaded with sorafenib and Spions for hepatocellular carcinoma theranostics","author":"Q Lin","year":"2025","unstructured":"Lin Q, Wen Y, Peng Y, Shi T, Liu K, Yu Q, et al. Cancer cell-coated PLGA nanoparticles loaded with sorafenib and Spions for hepatocellular carcinoma theranostics. Current Drug Delivery; 2025."},{"key":"3992_CR261","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-023-01660-2","volume":"9","author":"J Sun","year":"2023","unstructured":"Sun J, Liu Q, Jiang Y, Cai Z, Liu H, Zuo H. Engineered small extracellular vesicles loaded with miR-654-5p promote ferroptosis by targeting HSPB1 to alleviate sorafenib resistance in hepatocellular carcinoma. Cell Death Discov. 2023;9:362.","journal-title":"Cell Death Discov"},{"key":"3992_CR262","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.884369","volume":"12","author":"J Wang","year":"2022","unstructured":"Wang J, Wang X, Zhang X, Shao T, Luo Y, Wang W, et al. Extracellular vesicles and hepatocellular carcinoma: opportunities and challenges. Front Oncol. 2022;12:884369.","journal-title":"Front Oncol"},{"key":"3992_CR263","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107419","volume":"209","author":"L Cheng","year":"2024","unstructured":"Cheng L, Zhang L, Wang X, Wang Y, Yu J, Li M, et al. Extracellular vesicles in the HCC microenvironment: implications for therapy and biomarkers. Pharmacol Res. 2024;209:107419.","journal-title":"Pharmacol Res"},{"key":"3992_CR264","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-016-0430-z","volume":"35","author":"Z Qu","year":"2016","unstructured":"Qu Z, Wu J, Wu J, Luo D, Jiang C, Ding Y. Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro. J Exp Clin Cancer Res. 2016;35:159.","journal-title":"J Exp Clin Cancer Res"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-025-03992-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-025-03992-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-025-03992-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T03:03:17Z","timestamp":1769655797000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12951-025-03992-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":264,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3992"],"URL":"https:\/\/doi.org\/10.1186\/s12951-025-03992-w","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"assertion":[{"value":"9 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have reviewed the manuscript and provided their consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"89"}}